US20090081139A1 - Water-based delivery systems - Google Patents
Water-based delivery systems Download PDFInfo
- Publication number
- US20090081139A1 US20090081139A1 US12/082,406 US8240608A US2009081139A1 US 20090081139 A1 US20090081139 A1 US 20090081139A1 US 8240608 A US8240608 A US 8240608A US 2009081139 A1 US2009081139 A1 US 2009081139A1
- Authority
- US
- United States
- Prior art keywords
- delivery system
- dihydroxypropyl
- acid
- hydroxyethyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 150000002632 lipids Chemical class 0.000 claims abstract description 86
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 85
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 65
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 61
- 239000000194 fatty acid Substances 0.000 claims abstract description 61
- 229930195729 fatty acid Natural products 0.000 claims abstract description 61
- 229940106189 ceramide Drugs 0.000 claims abstract description 57
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 53
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 53
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 53
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000002243 precursor Substances 0.000 claims abstract description 43
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 42
- 210000003491 skin Anatomy 0.000 claims abstract description 42
- 239000013543 active substance Substances 0.000 claims abstract description 32
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 26
- 230000008591 skin barrier function Effects 0.000 claims abstract description 15
- 230000002708 enhancing effect Effects 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 110
- 150000003904 phospholipids Chemical class 0.000 claims description 52
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 239000002245 particle Substances 0.000 claims description 25
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 20
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 claims description 17
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 17
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 claims description 16
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims description 16
- 239000003872 25-hydroxy-cholecalciferol Substances 0.000 claims description 16
- 235000021318 Calcifediol Nutrition 0.000 claims description 16
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims description 16
- 230000000699 topical effect Effects 0.000 claims description 16
- 230000035515 penetration Effects 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 238000011065 in-situ storage Methods 0.000 claims description 14
- -1 butanoyl betulinic acid Chemical compound 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 11
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 239000000232 Lipid Bilayer Substances 0.000 claims description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 6
- HACYBABPVPSRAN-UHFFFAOYSA-N 2-hydroxy-n-(2-hydroxyethyl)-n-(2-hydroxyoctadecyl)propanamide Chemical compound CCCCCCCCCCCCCCCCC(O)CN(CCO)C(=O)C(C)O HACYBABPVPSRAN-UHFFFAOYSA-N 0.000 claims description 6
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 claims description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims description 6
- 229940114079 arachidonic acid Drugs 0.000 claims description 6
- 229940048864 ceramide 1 Drugs 0.000 claims description 6
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 6
- CZWCRWZKEOHQKD-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-(3-methylhexadecyl)acetamide Chemical compound CCCCCCCCCCCCCC(C)CCN(C(C)=O)CC(O)CO CZWCRWZKEOHQKD-UHFFFAOYSA-N 0.000 claims description 6
- STAGBCRZQPHITR-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxy-3-octadecoxypropyl)hexadecanamide Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CN(CCO)C(=O)CCCCCCCCCCCCCCC STAGBCRZQPHITR-UHFFFAOYSA-N 0.000 claims description 6
- LMXGJIYXKDRJOB-UHFFFAOYSA-N n-(3-dodecoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)propanamide Chemical compound CCCCCCCCCCCCOCC(O)CN(CCO)C(=O)CC LMXGJIYXKDRJOB-UHFFFAOYSA-N 0.000 claims description 6
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 6
- 230000002207 retinal effect Effects 0.000 claims description 6
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 6
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 6
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical class CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 5
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims description 5
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 5
- 229940044176 ceramide 3 Drugs 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims description 5
- 229940033329 phytosphingosine Drugs 0.000 claims description 5
- 229940108325 retinyl palmitate Drugs 0.000 claims description 5
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 5
- 239000011769 retinyl palmitate Substances 0.000 claims description 5
- 230000000475 sunscreen effect Effects 0.000 claims description 5
- 239000000516 sunscreening agent Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000006829 sphingolipid biosynthesis Effects 0.000 claims description 4
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- DKXVCOUJXFYMMW-UHFFFAOYSA-N 1-[acetyl(octadecyl)amino]-3-hydroxypropane-2-sulfonic acid Chemical compound CCCCCCCCCCCCCCCCCCN(C(C)=O)CC(CO)S(O)(=O)=O DKXVCOUJXFYMMW-UHFFFAOYSA-N 0.000 claims description 3
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims description 3
- YUVVZFXNFDQFLJ-UHFFFAOYSA-N 2-[decanoyl-(3-dodecoxy-2-hydroxypropyl)amino]-1-hydroxyethanesulfonic acid Chemical compound CCCCCCCCCCCCOCC(O)CN(CC(O)S(O)(=O)=O)C(=O)CCCCCCCCC YUVVZFXNFDQFLJ-UHFFFAOYSA-N 0.000 claims description 3
- CRIQWJGRJQTOIS-UHFFFAOYSA-N 2-[hexadecanoyl(2-hydroxyhexadecyl)amino]ethanesulfonic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N(CCS(O)(=O)=O)CC(O)CCCCCCCCCCCCCC CRIQWJGRJQTOIS-UHFFFAOYSA-N 0.000 claims description 3
- NHQLMDBWTPRUDU-UHFFFAOYSA-N 2-butyl-n-(2-hydroxydodecyl)-n-(2-hydroxyethyl)hexanamide Chemical compound CCCCCCCCCCC(O)CN(CCO)C(=O)C(CCCC)CCCC NHQLMDBWTPRUDU-UHFFFAOYSA-N 0.000 claims description 3
- NIONDZDPPYHYKY-UHFFFAOYSA-N 2-hexenoic acid Chemical compound CCCC=CC(O)=O NIONDZDPPYHYKY-UHFFFAOYSA-N 0.000 claims description 3
- WWGIJDONVZBVGT-UHFFFAOYSA-N 2-hydroxy-n-(2-hydroxydodecyl)-n-(2-hydroxyethyl)hexanamide Chemical compound CCCCCCCCCCC(O)CN(CCO)C(=O)C(O)CCCC WWGIJDONVZBVGT-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims description 3
- XOXXREIDHPYXSM-UHFFFAOYSA-N 3-[butanoyl(hexadecyl)amino]-2-hydroxypropane-1-sulfonic acid Chemical compound CCCCCCCCCCCCCCCCN(C(=O)CCC)CC(O)CS(O)(=O)=O XOXXREIDHPYXSM-UHFFFAOYSA-N 0.000 claims description 3
- JCYIVCPHTPAKNZ-UHFFFAOYSA-N 3-[dodecyl(heptanoyl)amino]-2-hydroxypropane-1-sulfonic acid Chemical compound CCCCCCCCCCCCN(CC(O)CS(O)(=O)=O)C(=O)CCCCCC JCYIVCPHTPAKNZ-UHFFFAOYSA-N 0.000 claims description 3
- KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 claims description 3
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims description 3
- HXQHFNIKBKZGRP-JRVLCRGASA-N 5,9,12-octadecatrienoic acid Chemical compound CCCCC\C=C\C\C=C\CC\C=C\CCCC(O)=O HXQHFNIKBKZGRP-JRVLCRGASA-N 0.000 claims description 3
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 241001116389 Aloe Species 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 235000021357 Behenic acid Nutrition 0.000 claims description 3
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- OPFAHECKMHQKGS-UHFFFAOYSA-N CCCCCCCCCCCCCCCCC(O)CN(CCP(=O)=O)C(=O)CCC Chemical compound CCCCCCCCCCCCCCCCC(O)CN(CCP(=O)=O)C(=O)CCC OPFAHECKMHQKGS-UHFFFAOYSA-N 0.000 claims description 3
- SCNBTKFLOIFIHT-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCN(C(C)=O)CC(O)CP(=O)=O Chemical compound CCCCCCCCCCCCCCCCCCN(C(C)=O)CC(O)CP(=O)=O SCNBTKFLOIFIHT-UHFFFAOYSA-N 0.000 claims description 3
- DRAGTMPCAKOQIR-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCN(CC(CO)P(=O)=O)C(=O)CCC Chemical compound CCCCCCCCCCCCCCCCCN(CC(CO)P(=O)=O)C(=O)CCC DRAGTMPCAKOQIR-UHFFFAOYSA-N 0.000 claims description 3
- NBZRHEFPJMXDET-UHFFFAOYSA-N CCCCCCCCCCCCCCCCOCC(O)CN(CCP(=O)=O)C(=O)CCCCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCCCCOCC(O)CN(CCP(=O)=O)C(=O)CCCCCCCCCCCCCCC NBZRHEFPJMXDET-UHFFFAOYSA-N 0.000 claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 3
- 208000001840 Dandruff Diseases 0.000 claims description 3
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 3
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 claims description 3
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- 239000005639 Lauric acid Substances 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 3
- 108090001090 Lectins Proteins 0.000 claims description 3
- 235000021353 Lignoceric acid Nutrition 0.000 claims description 3
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 240000009023 Myrrhis odorata Species 0.000 claims description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 3
- WAYLDHLWVYQNSQ-KEFDUYNTSA-N N-2-hydroxylignoceroylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC WAYLDHLWVYQNSQ-KEFDUYNTSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 3
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 3
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 claims description 3
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- ZGBFGAHZKZQSLG-UMCOJZBLSA-N [30-oxo-30-[[(e,2s,3r,6r)-1,3,6-trihydroxyoctadec-4-en-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCC[C@@H](O)\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC ZGBFGAHZKZQSLG-UMCOJZBLSA-N 0.000 claims description 3
- 229960004308 acetylcysteine Drugs 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 3
- 229960002916 adapalene Drugs 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- XJKITIOIYQCXQR-SCUNHAKFSA-N all-trans-retinyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XJKITIOIYQCXQR-SCUNHAKFSA-N 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 239000000058 anti acne agent Substances 0.000 claims description 3
- 229940124340 antiacne agent Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 claims description 3
- 229940011658 asiatic acid Drugs 0.000 claims description 3
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 229940116226 behenic acid Drugs 0.000 claims description 3
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 3
- 229930183167 cerebroside Natural products 0.000 claims description 3
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 claims description 3
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
- TUTWLYPCGCUWQI-UHFFFAOYSA-N decanamide Chemical compound CCCCCCCCCC(N)=O TUTWLYPCGCUWQI-UHFFFAOYSA-N 0.000 claims description 3
- 235000020960 dehydroascorbic acid Nutrition 0.000 claims description 3
- 239000011615 dehydroascorbic acid Substances 0.000 claims description 3
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 3
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims description 3
- 230000037336 dry skin Effects 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 3
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 3
- 229960002733 gamolenic acid Drugs 0.000 claims description 3
- 229940045109 genistein Drugs 0.000 claims description 3
- 235000006539 genistein Nutrition 0.000 claims description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 3
- 229940097042 glucuronate Drugs 0.000 claims description 3
- 229940124563 hair growth stimulant Drugs 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 239000002523 lectin Substances 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 3
- 235000019136 lipoic acid Nutrition 0.000 claims description 3
- IKJIZZGNRFNJCY-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-2-hydroxy-n-(2-methylhexadecyl)acetamide Chemical compound CCCCCCCCCCCCCCC(C)CN(C(=O)CO)CC(O)CO IKJIZZGNRFNJCY-UHFFFAOYSA-N 0.000 claims description 3
- JKSDTWYRKZQKGS-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-2-hydroxy-n-(2-methylhexadecyl)heptanamide Chemical compound CCCCCCCCCCCCCCC(C)CN(CC(O)CO)C(=O)C(O)CCCCC JKSDTWYRKZQKGS-UHFFFAOYSA-N 0.000 claims description 3
- KLRLSYUCCGXADL-UTJQPWESSA-N n-(2,3-dihydroxypropyl)-2-hydroxy-n-[(9z,12z)-octadeca-9,12-dienyl]heptanamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCN(CC(O)CO)C(=O)C(O)CCCCC KLRLSYUCCGXADL-UTJQPWESSA-N 0.000 claims description 3
- TZPSXKDAVGHVFI-NQLNTKRDSA-N n-(2,3-dihydroxypropyl)-2-hydroxy-n-[(9z,12z)-octadeca-9,12-dienyl]propanamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCN(C(=O)C(C)O)CC(O)CO TZPSXKDAVGHVFI-NQLNTKRDSA-N 0.000 claims description 3
- XEHILGDTTUNNLB-SEYXRHQNSA-N n-(2,3-dihydroxypropyl)-2-hydroxy-n-[(z)-octadec-9-enyl]heptanamide Chemical compound CCCCCCCC\C=C/CCCCCCCCN(CC(O)CO)C(=O)C(O)CCCCC XEHILGDTTUNNLB-SEYXRHQNSA-N 0.000 claims description 3
- GLAPQPSBGFKSIT-KHPPLWFESA-N n-(2,3-dihydroxypropyl)-2-hydroxy-n-[(z)-octadec-9-enyl]propanamide Chemical compound CCCCCCCC\C=C/CCCCCCCCN(C(=O)C(C)O)CC(O)CO GLAPQPSBGFKSIT-KHPPLWFESA-N 0.000 claims description 3
- MQJLKAOJGOCJHS-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-2-hydroxy-n-octadecylpentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(O)CO)C(=O)C(O)CCC MQJLKAOJGOCJHS-UHFFFAOYSA-N 0.000 claims description 3
- SPSUORBPPHDOAZ-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-2-hydroxy-n-octadecylpropanamide Chemical compound CCCCCCCCCCCCCCCCCCN(C(=O)C(C)O)CC(O)CO SPSUORBPPHDOAZ-UHFFFAOYSA-N 0.000 claims description 3
- GDANLFTZYKJYST-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-3-hydroxy-n-octadecylbutanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(O)CO)C(=O)CC(C)O GDANLFTZYKJYST-UHFFFAOYSA-N 0.000 claims description 3
- DMWDTRYRBYIPKK-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-4-hydroxy-n-tetradecylbutanamide Chemical compound CCCCCCCCCCCCCCN(CC(O)CO)C(=O)CCCO DMWDTRYRBYIPKK-UHFFFAOYSA-N 0.000 claims description 3
- YLDRNSWQROPOHU-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-(2-ethylhexadecyl)hexanamide Chemical compound CCCCCCCCCCCCCCC(CC)CN(CC(O)CO)C(=O)CCCCC YLDRNSWQROPOHU-UHFFFAOYSA-N 0.000 claims description 3
- YTTSJUAXNYHMJJ-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-(2-methylheptadecyl)propanamide Chemical compound CCCCCCCCCCCCCCCC(C)CN(C(=O)CC)CC(O)CO YTTSJUAXNYHMJJ-UHFFFAOYSA-N 0.000 claims description 3
- FHGHBNAOZOFYTJ-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-(3-ethyldodecyl)butanamide Chemical compound CCCCCCCCCC(CC)CCN(CC(O)CO)C(=O)CCC FHGHBNAOZOFYTJ-UHFFFAOYSA-N 0.000 claims description 3
- WVPIBGHHDCEIGW-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-(3-ethylheptadecyl)butanamide Chemical compound CCCCCCCCCCCCCCC(CC)CCN(CC(O)CO)C(=O)CCC WVPIBGHHDCEIGW-UHFFFAOYSA-N 0.000 claims description 3
- FVJYUKUHJRIJPU-NQLNTKRDSA-N n-(2,3-dihydroxypropyl)-n-[(9z,12z)-octadeca-9,12-dienyl]acetamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCN(C(C)=O)CC(O)CO FVJYUKUHJRIJPU-NQLNTKRDSA-N 0.000 claims description 3
- MSFLHKPZYRRBIT-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-dodec-6-enylhexadecanamide Chemical compound CCCCCCCCCCCCCCCC(=O)N(CC(O)CO)CCCCCC=CCCCCC MSFLHKPZYRRBIT-UHFFFAOYSA-N 0.000 claims description 3
- XYZXOJSIWFCBIV-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-dodecylbutanamide Chemical compound CCCCCCCCCCCCN(CC(O)CO)C(=O)CCC XYZXOJSIWFCBIV-UHFFFAOYSA-N 0.000 claims description 3
- HJDNKQQPYHETJN-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-dodecyldecanamide Chemical compound CCCCCCCCCCCCN(CC(O)CO)C(=O)CCCCCCCCC HJDNKQQPYHETJN-UHFFFAOYSA-N 0.000 claims description 3
- MHSFEHCGNGXYRY-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-heptadecylacetamide Chemical compound CCCCCCCCCCCCCCCCCN(C(C)=O)CC(O)CO MHSFEHCGNGXYRY-UHFFFAOYSA-N 0.000 claims description 3
- MGZQWNAUQAFVSK-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-heptadecylbutanamide Chemical compound CCCCCCCCCCCCCCCCCN(CC(O)CO)C(=O)CCC MGZQWNAUQAFVSK-UHFFFAOYSA-N 0.000 claims description 3
- IEZJTCNCKHDZND-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-hexadecyl-2-hydroxyhexanamide Chemical compound CCCCCCCCCCCCCCCCN(CC(O)CO)C(=O)C(O)CCCC IEZJTCNCKHDZND-UHFFFAOYSA-N 0.000 claims description 3
- HDGRBTWRJLIVGO-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-hexadecyl-2-hydroxyoctanamide Chemical compound CCCCCCCCCCCCCCCCN(CC(O)CO)C(=O)C(O)CCCCCC HDGRBTWRJLIVGO-UHFFFAOYSA-N 0.000 claims description 3
- IGFYNYMBUUWYFC-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-hexadecyl-2-hydroxypropanamide Chemical compound CCCCCCCCCCCCCCCCN(C(=O)C(C)O)CC(O)CO IGFYNYMBUUWYFC-UHFFFAOYSA-N 0.000 claims description 3
- PSCYATWDNNQEQS-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-hexadecylbutanamide Chemical compound CCCCCCCCCCCCCCCCN(CC(O)CO)C(=O)CCC PSCYATWDNNQEQS-UHFFFAOYSA-N 0.000 claims description 3
- YUCIZTTYQBUQSS-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-octadecylbutanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(O)CO)C(=O)CCC YUCIZTTYQBUQSS-UHFFFAOYSA-N 0.000 claims description 3
- UTOZSQDSIRUVAR-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-octadecylpropanamide Chemical compound CCCCCCCCCCCCCCCCCCN(C(=O)CC)CC(O)CO UTOZSQDSIRUVAR-UHFFFAOYSA-N 0.000 claims description 3
- QRZXHIAMFPILNV-UHFFFAOYSA-N n-(2-hydroxydodecyl)-n-(2-hydroxyethyl)hexanamide Chemical compound CCCCCCCCCCC(O)CN(CCO)C(=O)CCCCC QRZXHIAMFPILNV-UHFFFAOYSA-N 0.000 claims description 3
- WTMCLHZHGKTOHB-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxy-3-nonoxypropyl)propanamide Chemical compound CCCCCCCCCOCC(O)CN(CCO)C(=O)CC WTMCLHZHGKTOHB-UHFFFAOYSA-N 0.000 claims description 3
- QTNGGCWGWOCQIO-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxy-3-octadecoxypropyl)butanamide Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CN(CCO)C(=O)CCC QTNGGCWGWOCQIO-UHFFFAOYSA-N 0.000 claims description 3
- ATFSFQQHNYHKGA-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxy-3-octoxypropyl)pentanamide Chemical compound CCCCCCCCOCC(O)CN(CCO)C(=O)CCCC ATFSFQQHNYHKGA-UHFFFAOYSA-N 0.000 claims description 3
- XJXKJOUQWSEMDS-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxyhexadecyl)acetamide Chemical compound CCCCCCCCCCCCCCC(O)CN(C(C)=O)CCO XJXKJOUQWSEMDS-UHFFFAOYSA-N 0.000 claims description 3
- RMCOHIQDTBZQEY-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxyhexadecyl)butanamide Chemical compound CCCCCCCCCCCCCCC(O)CN(CCO)C(=O)CCC RMCOHIQDTBZQEY-UHFFFAOYSA-N 0.000 claims description 3
- DKNANAGUMWXJDN-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxyhexadecyl)heptanamide Chemical compound CCCCCCCCCCCCCCC(O)CN(CCO)C(=O)CCCCCC DKNANAGUMWXJDN-UHFFFAOYSA-N 0.000 claims description 3
- JZHJTATZQLOTSH-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxyoctadecyl)acetamide Chemical compound CCCCCCCCCCCCCCCCC(O)CN(C(C)=O)CCO JZHJTATZQLOTSH-UHFFFAOYSA-N 0.000 claims description 3
- WBIUOXITYIHXRU-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxyoctadecyl)hexadecanamide Chemical group CCCCCCCCCCCCCCCCC(O)CN(CCO)C(=O)CCCCCCCCCCCCCCC WBIUOXITYIHXRU-UHFFFAOYSA-N 0.000 claims description 3
- JDZJZPKWPHHBCK-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxyoctadecyl)propanamide Chemical compound CCCCCCCCCCCCCCCCC(O)CN(CCO)C(=O)CC JDZJZPKWPHHBCK-UHFFFAOYSA-N 0.000 claims description 3
- ADBNCSMUXRIFSI-UHFFFAOYSA-N n-(3-decoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)hexanamide Chemical compound CCCCCCCCCCOCC(O)CN(CCO)C(=O)CCCCC ADBNCSMUXRIFSI-UHFFFAOYSA-N 0.000 claims description 3
- KOMPHXZRWSXUTC-UHFFFAOYSA-N n-(3-dodecoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)butanamide Chemical compound CCCCCCCCCCCCOCC(O)CN(CCO)C(=O)CCC KOMPHXZRWSXUTC-UHFFFAOYSA-N 0.000 claims description 3
- RHMFJDNNJABGLZ-UHFFFAOYSA-N n-(3-dodecoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)heptanamide Chemical compound CCCCCCCCCCCCOCC(O)CN(CCO)C(=O)CCCCCC RHMFJDNNJABGLZ-UHFFFAOYSA-N 0.000 claims description 3
- BARNDYYNJWSIQR-UHFFFAOYSA-N n-(3-hexadecoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)-2-methylpropanamide Chemical compound CCCCCCCCCCCCCCCCOCC(O)CN(CCO)C(=O)C(C)C BARNDYYNJWSIQR-UHFFFAOYSA-N 0.000 claims description 3
- LXJZZDREMAECHV-UHFFFAOYSA-N n-(3-hexadecoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)acetamide Chemical compound CCCCCCCCCCCCCCCCOCC(O)CN(C(C)=O)CCO LXJZZDREMAECHV-UHFFFAOYSA-N 0.000 claims description 3
- PUGFCQQOYJMKOO-UHFFFAOYSA-N n-(3-hexadecoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)hexadecanamide Chemical compound CCCCCCCCCCCCCCCCOCC(O)CN(CCO)C(=O)CCCCCCCCCCCCCCC PUGFCQQOYJMKOO-UHFFFAOYSA-N 0.000 claims description 3
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
- 229960000249 pregnenolone Drugs 0.000 claims description 3
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 150000004508 retinoic acid derivatives Chemical class 0.000 claims description 3
- 229960000342 retinol acetate Drugs 0.000 claims description 3
- 235000019173 retinyl acetate Nutrition 0.000 claims description 3
- 239000011770 retinyl acetate Substances 0.000 claims description 3
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 229940071220 retinyl linoleate Drugs 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 206010040882 skin lesion Diseases 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims description 3
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 210000004087 cornea Anatomy 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 2
- ZSQBICJKPGRYFT-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-dodecyl-2-hydroxyoctanamide Chemical compound CCCCCCCCCCCCN(CC(O)CO)C(=O)C(O)CCCCCC ZSQBICJKPGRYFT-UHFFFAOYSA-N 0.000 claims 2
- SUYVLEXWZFFLHS-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-n-tetradecylacetamide Chemical compound CCCCCCCCCCCCCCN(C(C)=O)CC(O)CO SUYVLEXWZFFLHS-UHFFFAOYSA-N 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 64
- 239000006260 foam Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 230000004888 barrier function Effects 0.000 description 17
- 239000000230 xanthan gum Substances 0.000 description 11
- 229920001285 xanthan gum Polymers 0.000 description 11
- 235000010493 xanthan gum Nutrition 0.000 description 11
- 229940082509 xanthan gum Drugs 0.000 description 11
- 239000013020 final formulation Substances 0.000 description 10
- 229960004418 trolamine Drugs 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 7
- 235000004626 essential fatty acids Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000001783 ceramides Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000000736 corneocyte Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002884 Laureth 4 Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- OFUHPGMOWVHNPN-QWZFGMNQSA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (9z,12z)-octadeca-9,12-dienoate Chemical compound O1[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC2=C(C)C(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)=C(C)C(C)=C21 OFUHPGMOWVHNPN-QWZFGMNQSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 150000001841 cholesterols Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000003256 environmental substance Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229940061515 laureth-4 Drugs 0.000 description 2
- 239000013554 lipid monolayer Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- NTYZDAJPNNBYED-UHFFFAOYSA-M sodium;2-(2-dodecanoyloxypropanoyloxy)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O NTYZDAJPNNBYED-UHFFFAOYSA-M 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- KBUNOSOGGAARKZ-KRWDZBQOSA-N 3-dehydrosphinganine Chemical compound CCCCCCCCCCCCCCCC(=O)[C@@H](N)CO KBUNOSOGGAARKZ-KRWDZBQOSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229910000286 fullers earth Inorganic materials 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Definitions
- the present invention relates to a novel topical and mucosal delivery systems for drugs or any other active substance.
- the main demands on human skin are to prevent loss of water, and to prevent water and other matter of the environment from entering the body indiscriminately.
- the human skin thus forms a selectively permissible physical barrier between the human body and its surroundings.
- the barrier function has been shown to reside in the stratum corneum.
- the stratum corneum is the topmost layer of the skin, and is built of corneocytes.
- Corneocytes are cells that contain extensively cross-linked proteins, surrounded by a highly resistant cell envelope.
- the corneocytes are embedded in a bed of specific lipid structures of long chain lipids. These long chain lipids are organized as bilamellar structures stacked on top of each other. The bilamellar structures fill the intercellular spaces between the corneocytes.
- the skin has been described as a mosaic barrier model.
- This model envisages barrier lipids to exist predominantly in crystalline (gel) form.
- Such a form provides water impermeable domains, which are surrounded by so-called grain borders of lipids in a liquid crystalline state.
- This arrangement provides an effective, water tight barrier that still allows a minute but controlled loss of water through the liquid crystalline interdomains. This controlled water loss is enough to keep the keratin of the stratum corneum hydrated.
- the liquid character of the interdomain grain borders allows passage of hydrophilic and hydrophobic molecules on down-hill gradients, i.e. passage by passive diffusion.
- Dermal delivery systems are compositions which deliver active substances to, or through, the skin. These compositions typically contain skin permeation enhancers. Permeation enhancers may induce structural transformations of the bilamellar structure in the liquid crystalline interdomain regions, and thus promote transdermal delivery of, for example, pharmacological substances.
- Typical dermal delivery systems have an alcohol or petroleum base, with little consideration given to the biological properties of the vehicle itself.
- emulsified fatty acids can inherit certain detergent properties if their structure is significantly altered from those in the normal skin.
- the detergent properties can lead to disruption of the normal barrier function, which is counteractive to the potential benefit of the delivery system. Disruption of the normal barrier function often causes the stratum corneum to lose its natural potential to function properly as a barrier. As a result, the skin becomes either too dry or too permeable to environmental substances.
- barrier ointments Other conventional delivery systems that are thought to protect the skin from harmful substances are barrier ointments.
- the purpose of barrier ointments is to provide a film, and thereby create a layer which is impermeable to environmental substances. Due to the impermeability, though, these ointments both increase the body temperature of the treated body part, as well as prevent perspiration, and thus render an uncomfortable sensation.
- the dermal delivery systems described above are not formulated to deliver a substance to, or through, the human skin without permanently disrupting the stratum corneum's natural barrier function.
- the invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, and a ceramide.
- the delivery system also comprises at least one skin lipid precursor.
- the invention relates to delivery system for an active substance comprising water and lipophilic components, wherein the lipophilic components comprise fatty acids, cholesterol, and a ceramide/phospholipid portion, and wherein the lipophilic components are in the form of lipid particles, and gas spheres or vesicles.
- This delivery system can also comprise at least one skin lipid precursor.
- FIG. 1 is a diagram showing the gas spheres, lipid particles, vesicles and hydrophilic phase of the delivery systems.
- FIG. 2 is a diagram showing the components of the gas spheres of the delivery systems.
- FIG. 3 is a diagram showing the components of the lipid particles and of the vesicles of the delivery systems.
- FIG. 4 is a diagram showing the location of active substances within the various microcompartments of the delivery systems.
- the present invention provides an improved topical delivery system (skin preparation) formulated to deliver a substance to, or through, the human skin without permanently disrupting the stratum corneum's natural barrier function. Additionally, the topical delivery system of the present invention provides unique skin barrier restoration properties.
- the topical delivery system of the present invention is a water-based formulation comprising hydrophilic and lipophilic components.
- the delivery system comprises a water content exceeding 50%, such as more than 55%, 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 85%, 87%, 90%, 94%, 95% and 98%.
- the water content is between 60-80%, more preferably, between 70 and 80%.
- the topical delivery system is preferably designed, in its choice and composition of lipids, to resemble the normal lipid organization of the stratum corneum (horny layer), as much as possible.
- the system blends with the lipids naturally present in the stratum corneum, and easily penetrates the lipid bilayer of the skin. In doing so, the system carries along with it one or more active substances to be administered.
- the system enhances penetration of active substances into and/or through the stratum corneum, while the normal barrier properties of the stratum corneum are left intact, and/or are even functionally enhanced.
- the lipophilic component (i.e. lipids) of the system comprises fatty acids, cholesterol and a ceramide/phospholipid portion.
- the lipids are similar to those which make up the normal stratum corneum.
- the preferred ratio of the ceramide/phospholipid portion:cholesterol:fatty acid is in the range of approximately 2:1:1.5 to approximately 2.95:0.5:0.5. Preferably, for example, the ratio is approximately 2:1:1; more preferably the ratio is approximately 2.35:1:1.
- the fatty acids of the present invention can be any fatty acid, mixtures of fatty acids, salts of fatty acids, or mixtures of fatty acids and salts of fatty acids.
- the fatty acids can be saturated or unsaturated. Additionally, the fatty acids can comprise precursors of fatty acids. In a preferred embodiment, the fatty acids comprise ten, twelve, fourteen, sixteen, eighteen, twenty, twenty-two, or twenty-four carbon atoms, or any mixture of such fatty acids. A fatty acid mixture with a predominant portion of fatty acids which comprise a chain of sixteen or eighteen carbon atoms is most preferred.
- the delivery system can be prepared from a mixture of fatty acids of the following composition: at most about 2% of a component comprising a chain of fourteen carbon atoms, between about 47 and about 52% of a component comprising a chain of sixteen carbon atoms, between about 43 and about 48% of a component comprising a chain of eighteen carbon atoms, and at most about 1% of a component comprising a chain of twenty carbon atoms.
- Suitable saturated fatty acids for use in the delivery system include lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, and lignoceric acid.
- suitable unsaturated fatty acids include oleic acid, palmitoleic acid, linoleic acid, linolenic acid, and arachidonic acid.
- the delivery system contains an essential portion, such as about 90%, of such fatty acids.
- the preferred fatty acids are the essential fatty acids (EFAs).
- EFAs are essential for the plasma membrane formation of all cells. In keratinocytes, EFA deficiency makes cells hyperproliferative. Supplementation of EFAs reverses the hyperproliferation. EFAs also enhance lipid biosynthesis of the epidermis and provide lipids for the barrier formation of the epidermis.
- the essential fatty acids are preferably chosen from linoleic acid, ⁇ -linolenic acid, homo- ⁇ -linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid, timnodonic acid, hexaenoic acid, and mixtures thereof.
- the delivery system also comprises cholesterol, or derivatives of cholesterol such as, for example, lipid esters of cholesterol.
- the ceramide/phospholipid portion can comprise 100% ceramide, 100% phospholipids, or any other percent combination of ceramide and phospholipids.
- the ceramide/phospholipid portion can comprise 95% ceramide and 5% phospholipids, 90% ceramide and 10% phospholipids, 85% ceramide and 15% phospholipids, or 80% ceramide and 20% phospholipids.
- the ceramide component of the delivery system can be any ceramide or any mixture of ceramides.
- ceramides include pseudoceramides and neoceramides.
- the ceramide may be any of ceramide 1-7; and/or mixtures thereof.
- Some specific examples of ceramides include ceramide 1, ceramide 3, ceramide 4, ceramide 5, ceramide 6A, cerebrosides and ceramide 6B.
- pseudoceramides include:
- the phospholipid component may contain any phospholipid or mixtures of phospholipids.
- the phospholipid component comprises phosphatidycholine (PC).
- PC phosphatidycholine
- Other examples of phospholipids include distearoylphosphatidylcholine (DSPC 18), phosphatidic acid, inositol phosphate, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.
- the phospholipid component can comprise one or more lysophospholipids.
- Lysophospholipids are single chain phospholipids.
- Examples of lysophospholipids include lysophosphatidylcholines, such as monopalmitoylphosphatidylcholine (MPPC); lysophosphatidylglycerols; lysophosphatidylethanolamines; lysophosphatidylinositols; lysophosphatidylserines; and lysophosphatidic acid. Mixtures of different types of phospholipids and/or lysophospholipids can also be used.
- MPPC monopalmitoylphosphatidylcholine
- lysophosphatidylglycerols lysophosphatidylglycerols
- lysophosphatidylethanolamines lysophosphatidylinositols
- the present system also comprises skin lipid precursors.
- the lipid precursors include any compound that promotes in situ cholesterol, ceramide or sphingolipid synthesis.
- the preferred lipid precursors are mevalonic acid, which promotes in situ cholesterol synthesis; and 25-hydroxycholecalciferol, which promotes in situ ceramide synthesis in the skin.
- Other preferred precursors are palmitoyl CoA and serine, which together are converted to 3-ketosphinganine, which promotes in situ ceramide synthesis in the skin.
- the overall content of lipid in the system can be maintained in a range as low as approximately 2-20%. Therefore, the water content of the delivery system can be as high as 80-98%.
- the high water content enables the skin to “breathe” normally, and enhances its ability to restore its normal barrier function rapidly.
- lipid precursors useful in the present invention include, for example: acylceramides; deoxyacetein cimifugoside, adapalene, adenosine, aloe derived lectins, 3-aminopropyl dihydrogen phosphate, anise extracts, ascorbic acid and derivatives thereof, ascorbyl palmitate, asiatic acid, benzoic acid derivatives, biotin, butanoyl betulinic acid, cathecholamines, coenzyme Q10, dehydrocholesterol, dehydroascorbic acid and derivatives thereof, estrogen and derivatives, eythrobic acid, genistein, lipoic acid, 4-methoxysalicylic acid, N-acetylcysteine, panthetine, pregnenolone and derivatives, retinal, retinoates, retinal, retinyl acetate, retinyl glucuronate, retinyl linoleate,
- an alkaline compound or buffer system
- alkaline compounds include triethanolamine (TEA), sodium hydroxide, sodium acetate, and sodium bicarbonate.
- buffer systems include carbonic acid/potassium carbonate, phosphoric acid/potassium phosphate, and acetic acid/sodium acetate.
- the fatty acids of the final delivery system can be in a free state or can form a salt.
- the portion of fatty acids which is in a free state is partially dependent on the pH of the formulation.
- the level of free fatty acid increases as the pH of the formulation decreases.
- the pH of the formulation can vary.
- the pH of the formulation is about 6.5 to 7.8.
- the delivery system comprises triethanolamine (TEA). It is preferred to adapt the molar ratio between the fatty acids and triethanolamine to enable a certain portion of the fatty acids in the final delivery system to form a triethanolaminium salt, while another portion of the acid exists as free fatty acid.
- TAA triethanolamine
- the delivery system is prepared from fatty acids and triethanolamine in which the molar ratio of the fatty acids to the triethanolamine is higher than about 2:1, preferably higher than about 3:1.
- the delivery system comprises a combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and skin lipid precursors between about 2-20%.
- a preferred low end of this range is about 2%, 3%, 4%, 5%, 6%, 7% or 8%.
- a preferred high end of this range is about 13%, 14%, 15%, 16%, 17%, 18%, 19% and 20%.
- the amounts of the components of the delivery system are as follows: fatty acid: 0.5-10%; cholesterol: 0.5-10%; a ceramide/phospholipid portion: 0.005-20%; and lipid precursors: 0.000001-10%.
- the formulation does not contain any irritating ingredients.
- irritating ingredients include alcohols, such as isopropanol and ethanol; short chain fatty acids; and detergents.
- the formulation contains less than 10% alcohol, more preferably less than 5% alcohol, most preferably less than 1% alcohol, and optimally no alcohol.
- the administered formulation easily penetrates the lipid bilayer of the skin.
- the system creates a temporary and reversible state of enhanced atrophy among the lipid components of the bilayer.
- the enhanced atrophy in itself then gives rise to either a) enhanced energy levels, wherein the energy could promote active transport of the to-be-carried substances into the skin, and/or b) creates naturally and reversibly occurring holes and disorganized patches in the lipid bilayer through which the active substances could then pass more easily.
- the temporary disarray in the lipid bilayer will temporarily break up the organized structure of the bilayer and create micelles of lipids with areas between them, or surrounding them, through which lipophobic/hydrophilic substances and/or compositions can enter through the stratum corneum.
- the lipid composition of the formulation resembles the natural lipid composition of the skin, the so introduced new lipids will after a short time of creative chaos easily blend in with the natural lipid building stones of the lipid bilayer, and thus not permanently damage the barrier function of the skin.
- the normal barrier function of the cornea stratum rapidly returns. (That is, the skin barrier restoration is rapid.)
- the rapid return may be enhanced by the lipid precursors of the formulation.
- the in situ promotion of cholesterol synthesis in the stratum corneum, the in situ promotion of ceramide synthesis in the stratum corneum, and/or the in situ promotion of sphingolipid synthesis in the stratum corneum may allow for the rapid skin barrier restoration.
- a delivery system according to the present invention preferably comprises a combination of:
- Fatty Acid C16-24
- Phospholipid 0.5-10%
- Cholesterol 0.5-7%
- Lipid precursor 0.000001-10% Mevalonic acid and/or 25-Hydroxycholecalciferol Ceramide 0.005%-7% (Not all components are present are 0%.)
- Another preferred embodiment of the delivery system comprises:
- Fatty Acid C16-24
- Phospholipid 0.5-10%
- Cholesterol 0.5-7%
- Lipid precursor 0.000001-10% Mevalonic acid and/or 25-Hydroxycholecalciferol Ceramide 0.005%-7%
- Glycerine 0.000001-10%
- Propylene glycol 0-48%
- PVP e.g., M weight 40.000
- TEA TEA 0-3%
- An even more preferred embodiment of the delivery system comprises:
- the topical delivery system according to the present invention further comprises one or more cosmetically and/or therapeutically active substances.
- Active substances are defined as agents other than emollients and other than ingredients that merely improve the physical characteristics of the formulation.
- active substances include sunscreens, tanning agents, skin anti-wrinkling agents, anti-dandruff agents, anti-acne agents, hair growth stimulants and vitamins.
- Therapeutically active substances include, but are not limited to, substances which treat conditions such as eczema, dry skin, itchy skin, fungal infection, acne, skin cancer, hair loss, louse infection, psoriasis, and skin lesions (i.e. wounds).
- Therapeutically active substances also include substances for transdermal delivery, for example, interleukin, hormones, vaccines, nicotine, interferon, pain killers, peptides, proteins and vitamins.
- Active substances also include steroid hormones.
- Steroid hormones inhibit inflammation and hyperproliferation of the epidermis thus resulting in normalization of hypersensitive skin conditions.
- steroid hormones include, bat are not limited to, glucocorticoids, androgens and estrogens.
- sunscreens include those materials commonly employed to block ultraviolet light.
- Illustrative compounds are derivatives of PABA, cinnamate and salicylate.
- octyl methoxycinnamate and 2-hydroxy-4-methoxybenzophenone also known as oxybenzone
- Octyl methoxycinnamate and 2-hydroxy-4-methoxybenzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3, respectively.
- the exact amount of sunscreen employed in the systems can vary depending upon the degree of protection desired from the sun's UV radiation.
- vitamins examples include vitamin A and vitamin E, preferably in the form of an ester of a fatty acid, such as vitamin A palmitate (retinyl palmitate) and vitamin E linoleate (tocopheryl linoleate).
- esters of vitamins A and E may also be utilized, such as any of the fatty acids mentioned above and below.
- Preservatives may also be included in the formulations of the present invention. Suitable preservatives include alkyl esters of p-hydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Particularly preferred preservatives of this invention are methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroxyacetate and benzyl alcohol. Preservatives are typically used in amounts up to about 2% by weight of the formulation.
- adjunct minor components may also be incorporated into the formulations of the present invention. These components may include thickeners, coloring agents, opacifiers and perfumes. For example, any thickening agent can be included in the formulation to adjust the viscosity of the formulation. Examples of suitable thickening agents include glycerol and xanthan gum. Some additional adjunct minor components include chalk, talc, Fullers earth, kaolin, starch, smectites clays, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, aluminium starch octenyl succinate and mixtures thereof. Amounts of these adjunct minor components may range anywhere from 0.001 up to 20% by weight of the formulation (i.e. composition).
- the delivery system can be in any form, such as a cream, a lotion, a gel, and an aerosol foam.
- the amount of certain adjunct minor components used in a particular formulation varies depending on the desired form of the delivery system, as would be known by a skilled artisan.
- the amount of thickening agent used to prepare an aerosol foam formulation is about 10 to 20% of the amount used to prepare a cream formulation.
- emulsifiers are added to an aerosol foam formulation, such as, for example, laureth 4.
- the present invention provides a mucosal delivery system formulated to deliver a substance to, or through, a human mucous membrane without permanently disturbing the integrity of the mucous membrane.
- the mucous membrane is the moist tissue that lines some organs and body cavities (such as nose, mouth, lungs, rectum, stomach and vagina) and secretes mucous.
- the mucosal delivery system comprises the lipophilic and hydrophilic components, as described above. The particular formulations of the mucosal delivery systems are varied to accommodate the particular environment of the mucosa, as would be known by a skilled artisan.
- the lipophilic components of the topical or mucosal delivery system form three types of particles: gas spheres, vesicles, and lipid particles. These three types of particles are within a hydrophilic phase (i.e. aqueous medium). See FIG. 1 .
- the gas spheres are lipid monolayers that enclose air bubbles. These monolayers are formed from the lipophilic components. Negatively charged carboxylate groups stud the outer surfaces of these gas spheres. See FIG. 2 . Preferably, these gas spheres are approximately 1 ⁇ m to approximately 500 ⁇ m in diameter.
- the vesicles are lipid bilayers enclosing a hydrophilic core. These bilayers are formed from the lipophilic components. Negatively charged carboxylate groups stud the inner and outer surfaces of the vesicles. See FIG. 3 .
- the vesicles can range from approximately 0.02 ⁇ m to approximately 0.5 ⁇ m in diameter.
- the lipid particles are lipid monolayers enclosing fatty acids. These monolayers are formed from the lipophilic components. See FIG. 3 .
- the lipid particles are less than approximately 1 to approximately 150 ⁇ m in diameter.
- the lipid particles may be in the form of individual lipid particles, or the lipid particles may aggregate to form crystals.
- the various particles of the delivery system provide microcompartments with different properties. Due to these different microcompartments, the delivery system can be used to deliver both hydrophilic and lipophilic active substances.
- a water soluble active substance can be located in the hydrophilic core of the vesicles, or can be located in the hydrophilic phase of the system.
- a lipid soluble active substance can be located within the monolayer of the gas spheres, within the bilayer of the vesicles, or within the monolayer or within the core of the lipid particles. See FIG. 4 .
- the delivery systems comprise three phases, i.e. a foam phase, a vesicle phase and a hydrophilic phase.
- the foam phase comprises the gas spheres and the lipid particles.
- the vesicle phase comprises the vesicles and the lipid particles.
- the hydrophilic phase comprises water and hydrophilic components.
- the delivery system is produced from three portions (i.e. fractions), in particular a hydrophilic portion and two lipophilic portions.
- the two lipophilic portions comprise the lipophilic components as defined above. Both lipophilic portions are immersed in aqueous media.
- One portion is made into the foam phase.
- the other portion is made into the vesicle phase.
- the foam phase portion and the vesicle phase portion can be in a ratio from about 1:7 to about 7:1.
- the foam phase portion and the vesicle phase portion are approximately equal in amount.
- the foam phase is formed by mixing the foam phase portion at about 65 to 85° C.
- the pH is set to the range of about 5.5 to 8.2. The mixing is performed under conditions so as to allow gas spheres to form.
- the vesicle phase is formed by gently mixing the vesicle phase portion at about 65 to 85° C.
- the pH is set to the range of about 5.5 to 8.2.
- the vesicle phase portion is homogenized. Homogenization can be accomplished with, for example, a high pressure homogenizer or a sonicator.
- the pressure of the homogenizer can be set, for example, from about 10,000 to 40,000 psi.
- the vesicle phase is produced under conditions which do not allow any gas to enter the formulation, such as in a vacuum.
- the lipid particles, and/or lipid particle crystals form as a by-product of the formation of the foam phase and vesicle phase.
- up to 30% of the lipophilic components can be in the form of lipid particles and/or lipid particle crystals.
- the hydrophilic phase is formed by mixing together water soluble components with water (i.e. hydrophilic portion).
- water soluble components include propylene glycol, glycerol, polyvinylpyrrolidone, and thickeners, e.g., xanthan gum.
- the foam phase, vesicle phase and hydrophilic phases are mixed together.
- an equal amount of each phase is used in the formulation.
- the foam phase, vesicle phase and hydrophilic phases can be mixed together in any order.
- the foam phase and the vesicle phase can be first mixed together, and then the resulting mixture can be mixed with the hydrophilic phase.
- the foam phase can be first mixed with the hydrophilic phase, and then the vesicle phase can be added.
- One or more active substances can be added to the foam phase portion, the vesicle phase portion, the hydrophilic portion, or a combination of these portions.
- the specific components of a formulation, and the formulation process can be varied to obtain delivery systems which allow for different rates of the release, and degrees of penetration, of active substance(s).
- the phase of the system in which an active substance is placed affects release and penetration rates.
- a major portion of the active substance is placed within the vesicle phase portion.
- the size of the vesicles can be controlled via the formulation process. For example, during processing, as the homogenizing pressure and duration increases, the vesicle size decreases.
- An additional factor which affects release and penetration rates is the type of phospholipids used in the formulation. For example, penetration can be enhanced by including a greater portion of unsaturated phospholipids within the formulation.
- phospholipids which include elevated levels of surface active single chain agents enhance penetration.
- Surface active single chain agents at about a level of 2% to 10% of the phospholipids are considered to be at an elevated level.
- Examples of surface active agents are lysophospholipids
- An example of a phospholipid formulation comprises 95% phosphatidylcholine and 1.2% lysophosphatidylcholine. Such a formulation is sold as EPIKURON® 200 SH.
- a phospholipid formulation which provides enhanced penetration comprises 95% phosphatidylcholine and 3% lysophosphatidylcholine. Such a formulation is sold as EPIKURON® 200.
- the concentration of free fatty acid is also an important parameter affecting penetration rates.
- a relatively high level of free fatty acid enhances penetration of hydrophilic active substances.
- Penetration rates can also be enhanced by the addition of certain adjuvants.
- an anionic surfactant can be added to the foam phase portion.
- incorporation of glyceryidilaurate into the vesicle bilayers creates more flexible vesicles which can enhance penetration.
- Additional factors which affect release and penetration rates include: the ratio between the different lipid components; the ratio between the foam phase, the vesicle phase and the hydrophilic phase; and the ratio between the amounts of active substances within each phase.
- the lipophilic components of the delivery system form only two of the above-defined particles. That is, the formulation comprises only the gas spheres and lipid particles; or the formulation comprises only the vesicles and lipid particles.
- the delivery system is produced from a hydrophilic portion and a lipophilic portion.
- the lipophilic portion is made either into the foam phase or the vesicle phase, as described above.
- the vesicle phase is produced under conditions which do not allow any gas to enter the formulation, such as in a vacuum.
- the foam phase or vesicle phase is mixed with the hydrophilic phase.
- an equal amount of either the foam phase or vesicle phase, and the hydrophilic phase is used in the formulation.
- the phospholipid, cholesterol, palmitic acid and ceramide components are mixed together with water, and agitated at a temperature of 70-80° C.
- the following additional components are added: mevalonic acid lactone, 25-hydroxycholecalciferol, propylene glycol, glycerine, PVP, TEA added along with water, and sodium hydroxide.
- Sodium hydroxide is added to adjust viscosity and stabilize the formulation. Water is then added, and the formulation is agitated well. The formulation is then cooled down.
- An active substance can be dissolved in both the lipid phase and/or the water phase, depending on the solubility and concentration of the active substance.
- PC phosphatidylcholine
- “Skinflux” is a blend product obtainable from Degussa Goldschmidt which contains: Ceramide 1, 3, 6II; Phytosphingosine; Cholesterol; Sodium Lauroyl Lactylate; Carbomer; and Xanthan Gum.
- Mevalonic acid lactone is a lipid precursor for cholesterol/fatty acids.
- 25-Hydroxycholecalciferol is a lipid precursor for ceramides
- Xanthan Gum is a thickener (polysaccharide).
- PHENONIP ® is a preservative and a blend of parabens.
- a vesicle fraction Three fractions, a vesicle fraction, a foam fraction and a hydrophilic fraction, are first prepared separately, as described below. Each fraction weighs 3.3 kg. Then the three fractions are mixed together. The following tables show the percent amount of each component contributed by each fraction to the final formulation. Thus, for each component, the sum of the percent amounts of all the fractions is 100%.
- Percent Amount in Final Component Formulation Water 33% of total water Hydrogenated lecithins 50% of total amount Palmitic acid 50% of total amount Cholesterol 50% of total amount Mevalonic acid 50% of total amount Triethanol amine 50% of total amount Preservative (e.g., Paraben mixture) 50% of total amount Xanthan gum 15% of total amount Skinflux 33% of total amount 25-hydroxycholecalciferol 50% of total amount 5M sodium hydroxide 1.3 ml per 1000 grams of water The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the vesicle fraction to the final formulation.
- the components are mixed and heated to the temperature range of 65 to 85° C. while gently stirring.
- the pH is set to the range of 5.5 to 8.2 by the use of sodium hydroxide.
- the resulting mixture is then homogenized. Homogenization can be accomplished by, for example, a homogenizer set at a high pressure (e.g. 10,000 to 40,000 psi); or by a sonicator.
- the size of the vesicles is partially dependent upon how long the resulting mixture is agitated. For example, to obtain an average vesicle size of 0.140 ⁇ m, the resulting mixture is agitated for 60 minutes at about 70° C. The mixture is then allowed to cool to below 40° C.
- Percent Amount in Final Component Formulation Water 33% of total water Hydrogenated lecithins 50% of total amount Palmitic acid 50% of total amount Cholesterol 50% of total amount Mevalonic acid 50% of total amount Triethanol amine 50% of total amount Preservative (e.g. a paraben mixture) 50% of total amount Xanthan gum 7.5% of total amount Skinflux 33% of total amount 25-hydroxycholecalciferol 50% of total amount 5M sodium hydroxide 1.3 ml per 1000 g of water The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the foam fraction to the final formulation.
- the components are mixed and heated to the temperature range of 65 to 85° C. while stirring.
- the pH is set to the range of 5.5 to 8.2 by the use of sodium hydroxide.
- the composition is mixed vigorously for 1 minute. Mixing can be done with ULTRATURRAX® from IKA Werke, Janke & Kunkel GmbH & Co KG (Staufen, Germany). The composition is then allowed to cool to below 40° C.
- Percent Amount in Final Component Formulation Water 34% of total water Propylene glycol 100% of total amount Glycerol 100% of total amount Polyvinylpyrrolidone 100% of total amount Xanthan gum 77.5% of total amount Skinflux 34% of total amount 5M sodium hydroxide 3.0 ml per 1000 g of water
- Percent Amount in Final Formulation indicates the percentage of each component which is contributed by the hydrophilic fraction to the final formulation.
- the components are mixed and heated to the temperature range of 65 to 85° C. while stirring.
- the pH is set to the range of 5.5 to 8.2 by use of sodium hydroxide. Once homogeneous, the composition is then allowed to cool to below 40° C.
- the three fractions are mixed together in any order.
- the foam fraction is added to the vesicle fraction and gently mixed.
- the hydrophilic fraction is added.
- the resulting mixture is gently blended for several minutes to obtain a homogeneous solution.
- the delivery system of this example is in the form of a cream.
- the total amount of xanthan gum in the final formulation is reduced from 2% to about 0.3%.
- an emulsifier is added, such as laureth 4.
- the emulsifier makes up about 0.7% of the final formulation.
- enhancing skin barrier restoration can be measured by tape and/or acetone striping of stratum corneum skin lipid content before, during and after a treatment period with the present invention and other systems. Then HPLC analysis of skin lipid content of stratum corneum is conducted.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor.
Description
- This application claims the benefit of U.S. Provisional Application No. 60/365,059, filed Mar. 13, 2002, which is incorporated herein by reference.
- The present invention relates to a novel topical and mucosal delivery systems for drugs or any other active substance.
- The main demands on human skin are to prevent loss of water, and to prevent water and other matter of the environment from entering the body indiscriminately. The human skin thus forms a selectively permissible physical barrier between the human body and its surroundings.
- The barrier function has been shown to reside in the stratum corneum. The stratum corneum is the topmost layer of the skin, and is built of corneocytes. Corneocytes are cells that contain extensively cross-linked proteins, surrounded by a highly resistant cell envelope. The corneocytes are embedded in a bed of specific lipid structures of long chain lipids. These long chain lipids are organized as bilamellar structures stacked on top of each other. The bilamellar structures fill the intercellular spaces between the corneocytes.
- To account for the skin's barrier properties, and for its selective hydrophilic and hydrophobic pathways, the skin has been described as a mosaic barrier model. This model envisages barrier lipids to exist predominantly in crystalline (gel) form. Such a form provides water impermeable domains, which are surrounded by so-called grain borders of lipids in a liquid crystalline state. This arrangement provides an effective, water tight barrier that still allows a minute but controlled loss of water through the liquid crystalline interdomains. This controlled water loss is enough to keep the keratin of the stratum corneum hydrated. The liquid character of the interdomain grain borders allows passage of hydrophilic and hydrophobic molecules on down-hill gradients, i.e. passage by passive diffusion.
- Dermal delivery systems are compositions which deliver active substances to, or through, the skin. These compositions typically contain skin permeation enhancers. Permeation enhancers may induce structural transformations of the bilamellar structure in the liquid crystalline interdomain regions, and thus promote transdermal delivery of, for example, pharmacological substances.
- Typical dermal delivery systems have an alcohol or petroleum base, with little consideration given to the biological properties of the vehicle itself. For example, emulsified fatty acids can inherit certain detergent properties if their structure is significantly altered from those in the normal skin. The detergent properties can lead to disruption of the normal barrier function, which is counteractive to the potential benefit of the delivery system. Disruption of the normal barrier function often causes the stratum corneum to lose its natural potential to function properly as a barrier. As a result, the skin becomes either too dry or too permeable to environmental substances.
- Other conventional delivery systems that are thought to protect the skin from harmful substances are barrier ointments. The purpose of barrier ointments is to provide a film, and thereby create a layer which is impermeable to environmental substances. Due to the impermeability, though, these ointments both increase the body temperature of the treated body part, as well as prevent perspiration, and thus render an uncomfortable sensation.
- The dermal delivery systems described above are not formulated to deliver a substance to, or through, the human skin without permanently disrupting the stratum corneum's natural barrier function.
- In one embodiment, the invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, and a ceramide. In another embodiment, the delivery system also comprises at least one skin lipid precursor.
- In an additional embodiment, the invention relates to delivery system for an active substance comprising water and lipophilic components, wherein the lipophilic components comprise fatty acids, cholesterol, and a ceramide/phospholipid portion, and wherein the lipophilic components are in the form of lipid particles, and gas spheres or vesicles. This delivery system can also comprise at least one skin lipid precursor.
-
FIG. 1 is a diagram showing the gas spheres, lipid particles, vesicles and hydrophilic phase of the delivery systems. -
FIG. 2 is a diagram showing the components of the gas spheres of the delivery systems. -
FIG. 3 is a diagram showing the components of the lipid particles and of the vesicles of the delivery systems. -
FIG. 4 is a diagram showing the location of active substances within the various microcompartments of the delivery systems. - The present invention provides an improved topical delivery system (skin preparation) formulated to deliver a substance to, or through, the human skin without permanently disrupting the stratum corneum's natural barrier function. Additionally, the topical delivery system of the present invention provides unique skin barrier restoration properties.
- All percentages given below are indicated in percent by weight. All numbers are approximate.
- The topical delivery system of the present invention is a water-based formulation comprising hydrophilic and lipophilic components. In a preferred embodiment, the delivery system comprises a water content exceeding 50%, such as more than 55%, 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 85%, 87%, 90%, 94%, 95% and 98%. Preferably, the water content is between 60-80%, more preferably, between 70 and 80%.
- The topical delivery system is preferably designed, in its choice and composition of lipids, to resemble the normal lipid organization of the stratum corneum (horny layer), as much as possible. Upon administration, the system (formulation) blends with the lipids naturally present in the stratum corneum, and easily penetrates the lipid bilayer of the skin. In doing so, the system carries along with it one or more active substances to be administered. The system enhances penetration of active substances into and/or through the stratum corneum, while the normal barrier properties of the stratum corneum are left intact, and/or are even functionally enhanced.
- The lipophilic component (i.e. lipids) of the system comprises fatty acids, cholesterol and a ceramide/phospholipid portion. The lipids are similar to those which make up the normal stratum corneum. The preferred ratio of the ceramide/phospholipid portion:cholesterol:fatty acid is in the range of approximately 2:1:1.5 to approximately 2.95:0.5:0.5. Preferably, for example, the ratio is approximately 2:1:1; more preferably the ratio is approximately 2.35:1:1.
- The fatty acids of the present invention can be any fatty acid, mixtures of fatty acids, salts of fatty acids, or mixtures of fatty acids and salts of fatty acids. The fatty acids can be saturated or unsaturated. Additionally, the fatty acids can comprise precursors of fatty acids. In a preferred embodiment, the fatty acids comprise ten, twelve, fourteen, sixteen, eighteen, twenty, twenty-two, or twenty-four carbon atoms, or any mixture of such fatty acids. A fatty acid mixture with a predominant portion of fatty acids which comprise a chain of sixteen or eighteen carbon atoms is most preferred.
- For example, the delivery system can be prepared from a mixture of fatty acids of the following composition: at most about 2% of a component comprising a chain of fourteen carbon atoms, between about 47 and about 52% of a component comprising a chain of sixteen carbon atoms, between about 43 and about 48% of a component comprising a chain of eighteen carbon atoms, and at most about 1% of a component comprising a chain of twenty carbon atoms.
- Examples of suitable saturated fatty acids for use in the delivery system include lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, and lignoceric acid. Examples of suitable unsaturated fatty acids include oleic acid, palmitoleic acid, linoleic acid, linolenic acid, and arachidonic acid. Preferably, the delivery system contains an essential portion, such as about 90%, of such fatty acids.
- The preferred fatty acids are the essential fatty acids (EFAs). EFAs are essential for the plasma membrane formation of all cells. In keratinocytes, EFA deficiency makes cells hyperproliferative. Supplementation of EFAs reverses the hyperproliferation. EFAs also enhance lipid biosynthesis of the epidermis and provide lipids for the barrier formation of the epidermis. The essential fatty acids are preferably chosen from linoleic acid, γ-linolenic acid, homo-γ-linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid, timnodonic acid, hexaenoic acid, and mixtures thereof.
- The delivery system also comprises cholesterol, or derivatives of cholesterol such as, for example, lipid esters of cholesterol.
- The ceramide/phospholipid portion can comprise 100% ceramide, 100% phospholipids, or any other percent combination of ceramide and phospholipids. For example, the ceramide/phospholipid portion can comprise 95% ceramide and 5% phospholipids, 90% ceramide and 10% phospholipids, 85% ceramide and 15% phospholipids, or 80% ceramide and 20% phospholipids.
- The ceramide component of the delivery system can be any ceramide or any mixture of ceramides. In this specification, ceramides include pseudoceramides and neoceramides.
- For example, the ceramide may be any of ceramide 1-7; and/or mixtures thereof. Some specific examples of ceramides include ceramide 1, ceramide 3, ceramide 4, ceramide 5, ceramide 6A, cerebrosides and ceramide 6B.
- Some examples of pseudoceramides include:
- N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)hexadecanamide
- N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)propanamide
- N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)butanamide
- N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)heptanamide
- N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)ethanamide
- N-(2-hydroxyoctadecyl)-N-(2-O-glucopyranosyl)ethylpentanamide
- N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)hexanamide
- N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2butylhexanamide
- N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)ethanamide
- N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2-hydroxyhexanamide
- N-(2-hydroxytetraadecyl)-N-(2-hydroxyethyl)propanamide
- N-(2-hydroxyhexadecyl)-N-(2-sulfoethyl)hexadecanamide
- N-(2-hydroxyoctadecyl)-N-(2-phosphoethyl)butanamide
- N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide
- N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide
- N-(2-hydroxy-3-nonanyloxypropyl)-N-(2-hydroxyethyl)propanamide
- N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide
- N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide
- N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)butanamide
- N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide
- N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-sulfohydroxyethyl)decanamide
- N-(2-hydroxy-3-decyloxypropyl)-N-(2-hydroxyethyl)hexanamide
- N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide
- N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)butanamide
- N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)co-o-linoleoyldocosanamide
- N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide
- N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)-2-methylpropanamide
- N-(2-hydroxy-3-tetraadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide
- N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)heptanamide
- N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-phosphoethyl)hexadecanamide
- N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide
- N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-)-glucopyranosyl)ethyl-2-hydroxypropanamide
- N-(2-hydroxy-3-octyloxypropyl)-N-(2-hydroxyethyl)pentanamide
Some examples of neoceramides include: - N-(2,3-dihydroxypropyl)-N-(hexadecyl)butanamide
- N-(2,3-dihydroxypropyl)-N-tetradecyl)ethanamide
- N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxypropanamide
- N-(2,3-dihydroxypropyl)-N-(octadecyl)butanamide
- N-(2,3-dihydroxypropyl)-N-(2-ethylhexadecyl)hexanamide
- N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyoctanamide
- N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide
- N-(2,3-dihydroxypropyl)-N-(dodecyl)butanamide
- N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyhexanamide
- N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)octanamide
- N-(2-hydroxy-3-phosphopropyl)-N-(octadecyl)ethanamide
- N-(2-hydroxy-3-sulfopropyl)-N-(hexadecyl)butanamide
- N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)decanamide
- N-(2,3-dihydroxypropyl)-N-(heptadecyl)ethanamide
- N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide
- N-(2,3-dihydroxypropyl)-N-(heptadecyl)butanamide
- N-(2,3-dihydroxypropyl)-N-(6-dodecenyl)hexadecan-amide
- N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxy-ethanamide
- N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypropan-amide
- N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(heptadecyl)-ethanamide
- N-(2-hydroxy-3-sulfopropyl)-N-(dodecyl)heptanamide
- N-(2,3-dihydroxypropyl)-N-(tetradecyl)-4-hydroxybutanamide
- N-(2,3-dihydroxypropyl)-N-octadecyl)-(t)-O-linoleoyl-docosanamide
- N-(2,3-dihydroxypropyl)-N-(linoleyl)ethanamide
- N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxy-heptan-amide
- N-(2,3-dihydroxypropyl)-N-iyiodecyl)-(t)-O-linoleoyidocosanamide
- N-(2,3-dihydroxypropyl)-N-(octadecyl)-3-hydroxybutanamide
- N-(2-phospho-3hydroxypropyl)-N-(heptadecyl)butanamide
- N-(2,3-dihydroxypropyl)-N-(2-methylheptadecyl)propanamide
- N-(2,3-dihydroxypropyl)-N-(3-ethylheptadecyl)butanamide
- N-(2-sulfo-3-hydroxypropyl)-N-(1-octadecyl)ethanamide
- N-(2,3-dihydroxypropyl)-N-(octadecyl)propanamide
- N-(2,3-dihydroxypropyl)-N-(dodecyl)decanamide
- N-(2,3-dihydroxypropyl)-N-(3-ethyldodecyl)butanamide
- N-(2-O-glucopyranosyl-3-hydroxy propyl)-N-(heptadecyl)butanamide
- N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxypropanamide
- N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxyheptanamide
- N-(2,3-dihydroxypropyl)-N-dodecyl)-2-hydroxyoctanamide
- N-(2,3-dihydroxypropyl)-N(hexadecyl)-2-methylheptanamide
- N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypentanamide
- N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxyheptanamide
- N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxypropanamide
- N-(2; 3-dihydroxypropyl)-N-(tetradecyl)ethanamide.
- The phospholipid component may contain any phospholipid or mixtures of phospholipids. Preferably the phospholipid component comprises phosphatidycholine (PC). Other examples of phospholipids include distearoylphosphatidylcholine (DSPC 18), phosphatidic acid, inositol phosphate, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.
- Additionally, the phospholipid component can comprise one or more lysophospholipids. Lysophospholipids are single chain phospholipids. Examples of lysophospholipids include lysophosphatidylcholines, such as monopalmitoylphosphatidylcholine (MPPC); lysophosphatidylglycerols; lysophosphatidylethanolamines; lysophosphatidylinositols; lysophosphatidylserines; and lysophosphatidic acid. Mixtures of different types of phospholipids and/or lysophospholipids can also be used.
- In a preferred embodiment, the present system also comprises skin lipid precursors. The lipid precursors include any compound that promotes in situ cholesterol, ceramide or sphingolipid synthesis. The preferred lipid precursors are mevalonic acid, which promotes in situ cholesterol synthesis; and 25-hydroxycholecalciferol, which promotes in situ ceramide synthesis in the skin. Other preferred precursors are palmitoyl CoA and serine, which together are converted to 3-ketosphinganine, which promotes in situ ceramide synthesis in the skin.
- By the promotion of in situ cholesterol and ceramide synthesis in the skin, the overall content of lipid in the system can be maintained in a range as low as approximately 2-20%. Therefore, the water content of the delivery system can be as high as 80-98%. The high water content enables the skin to “breathe” normally, and enhances its ability to restore its normal barrier function rapidly.
- Other lipid precursors useful in the present invention include, for example: acylceramides; deoxyacetein cimifugoside, adapalene, adenosine, aloe derived lectins, 3-aminopropyl dihydrogen phosphate, anise extracts, ascorbic acid and derivatives thereof, ascorbyl palmitate, asiatic acid, benzoic acid derivatives, biotin, butanoyl betulinic acid, cathecholamines, coenzyme Q10, dehydrocholesterol, dehydroascorbic acid and derivatives thereof, estrogen and derivatives, eythrobic acid, genistein, lipoic acid, 4-methoxysalicylic acid, N-acetylcysteine, panthetine, pregnenolone and derivatives, retinal, retinoates, retinal, retinyl acetate, retinyl glucuronate, retinyl linoleate, retinyl palmitate, retinyl proprionate, phytosphingosine, sphingosine, and others.
- Preferably, an alkaline compound, or buffer system, is included in the formulation to adjust the pH. Examples of alkaline compounds include triethanolamine (TEA), sodium hydroxide, sodium acetate, and sodium bicarbonate. Examples of buffer systems include carbonic acid/potassium carbonate, phosphoric acid/potassium phosphate, and acetic acid/sodium acetate.
- The fatty acids of the final delivery system can be in a free state or can form a salt. The portion of fatty acids which is in a free state is partially dependent on the pH of the formulation. In general, the level of free fatty acid increases as the pH of the formulation decreases. Depending upon the particular use of the formulation, the pH of the formulation can vary. Preferably, the pH of the formulation is about 6.5 to 7.8.
- In a preferred embodiment, the delivery system comprises triethanolamine (TEA). It is preferred to adapt the molar ratio between the fatty acids and triethanolamine to enable a certain portion of the fatty acids in the final delivery system to form a triethanolaminium salt, while another portion of the acid exists as free fatty acid. Preferably, the delivery system is prepared from fatty acids and triethanolamine in which the molar ratio of the fatty acids to the triethanolamine is higher than about 2:1, preferably higher than about 3:1.
- In a preferred embodiment, the delivery system comprises a combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and skin lipid precursors between about 2-20%. A preferred low end of this range is about 2%, 3%, 4%, 5%, 6%, 7% or 8%. A preferred high end of this range is about 13%, 14%, 15%, 16%, 17%, 18%, 19% and 20%.
- In another preferred embodiment, the amounts of the components of the delivery system are as follows: fatty acid: 0.5-10%; cholesterol: 0.5-10%; a ceramide/phospholipid portion: 0.005-20%; and lipid precursors: 0.000001-10%.
- In a preferred embodiment, the formulation does not contain any irritating ingredients. Examples of irritating ingredients include alcohols, such as isopropanol and ethanol; short chain fatty acids; and detergents. Preferably, the formulation contains less than 10% alcohol, more preferably less than 5% alcohol, most preferably less than 1% alcohol, and optimally no alcohol.
- Without the intention to limit the scope of the invention, a possible theory explaining the mechanical properties of the delivery system follows. The administered formulation easily penetrates the lipid bilayer of the skin. In doing so, the system creates a temporary and reversible state of enhanced atrophy among the lipid components of the bilayer. The enhanced atrophy in itself then gives rise to either a) enhanced energy levels, wherein the energy could promote active transport of the to-be-carried substances into the skin, and/or b) creates naturally and reversibly occurring holes and disorganized patches in the lipid bilayer through which the active substances could then pass more easily. It is very well feasible that the temporary disarray in the lipid bilayer will temporarily break up the organized structure of the bilayer and create micelles of lipids with areas between them, or surrounding them, through which lipophobic/hydrophilic substances and/or compositions can enter through the stratum corneum. As the lipid composition of the formulation resembles the natural lipid composition of the skin, the so introduced new lipids will after a short time of creative chaos easily blend in with the natural lipid building stones of the lipid bilayer, and thus not permanently damage the barrier function of the skin.
- Following the temporary disarray in the lipid bilayer, the normal barrier function of the cornea stratum rapidly returns. (That is, the skin barrier restoration is rapid.) The rapid return may be enhanced by the lipid precursors of the formulation. For example, the in situ promotion of cholesterol synthesis in the stratum corneum, the in situ promotion of ceramide synthesis in the stratum corneum, and/or the in situ promotion of sphingolipid synthesis in the stratum corneum may allow for the rapid skin barrier restoration.
- A delivery system according to the present invention preferably comprises a combination of:
-
Fatty Acid (C16-24) 0.5-10% Phospholipid 0.5-10% Cholesterol 0.5-7% Lipid precursor: 0.000001-10% Mevalonic acid and/or 25-Hydroxycholecalciferol Ceramide 0.005%-7% (Not all components are present are 0%.)
Another preferred embodiment of the delivery system comprises: -
Fatty Acid (C16-24) 0.5-10% Phospholipid 0.5-10% Cholesterol 0.5-7% Lipid precursor: 0.000001-10% Mevalonic acid and/or 25-Hydroxycholecalciferol Ceramide 0.005%-7% Glycerine 0-5% Propylene glycol 0-48% PVP (e.g., M weight 40.000) 0-5% TEA 0-3% (Not all components are present are 0%.)
An even more preferred embodiment of the delivery system comprises: -
Fatty Acid (C16-24) 2% Phospholipid 4.5% Cholesterol 2% Lipid precursor: 0.000001-10% Mevalonic acid and/or 1% or 0.01% 25-Hydroxycholecalciferol 0.015% or 0.0015% Ceramide 3 0.015% Glycerine 3% Propylene glycol 4% PVP (M weight 40.000) 2% TEA 0.5%
An even more preferred embodiment of the delivery system comprises: -
Fatty Acid (C16-24) 2% Phospholipid 4.5% Cholesterol 2% Lipid precursor: 0.000001-10% Mevalonic acid and/or 1% or 0.01% 25-Hydroxycholecalciferol 0.015% or 0.0015% Ceramide 3 0.015% Glycerine 3% Propylene glycol 4% PVP (M weight 40.000) 2% TEA 0.5% Ceramide 1 0.025% - The topical delivery system according to the present invention further comprises one or more cosmetically and/or therapeutically active substances. Active substances are defined as agents other than emollients and other than ingredients that merely improve the physical characteristics of the formulation.
- Some general examples of active substances include sunscreens, tanning agents, skin anti-wrinkling agents, anti-dandruff agents, anti-acne agents, hair growth stimulants and vitamins. Therapeutically active substances include, but are not limited to, substances which treat conditions such as eczema, dry skin, itchy skin, fungal infection, acne, skin cancer, hair loss, louse infection, psoriasis, and skin lesions (i.e. wounds). Therapeutically active substances also include substances for transdermal delivery, for example, interleukin, hormones, vaccines, nicotine, interferon, pain killers, peptides, proteins and vitamins.
- Active substances also include steroid hormones. Steroid hormones inhibit inflammation and hyperproliferation of the epidermis thus resulting in normalization of hypersensitive skin conditions. Examples of steroid hormones include, bat are not limited to, glucocorticoids, androgens and estrogens.
- Examples of sunscreens include those materials commonly employed to block ultraviolet light. Illustrative compounds are derivatives of PABA, cinnamate and salicylate. For example, octyl methoxycinnamate and 2-hydroxy-4-methoxybenzophenone (also known as oxybenzone) can be used. Octyl methoxycinnamate and 2-hydroxy-4-methoxybenzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3, respectively. The exact amount of sunscreen employed in the systems can vary depending upon the degree of protection desired from the sun's UV radiation.
- Examples of vitamins include vitamin A and vitamin E, preferably in the form of an ester of a fatty acid, such as vitamin A palmitate (retinyl palmitate) and vitamin E linoleate (tocopheryl linoleate). Other esters of vitamins A and E may also be utilized, such as any of the fatty acids mentioned above and below.
- Preservatives may also be included in the formulations of the present invention. Suitable preservatives include alkyl esters of p-hydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Particularly preferred preservatives of this invention are methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroxyacetate and benzyl alcohol. Preservatives are typically used in amounts up to about 2% by weight of the formulation.
- Other adjunct minor components may also be incorporated into the formulations of the present invention. These components may include thickeners, coloring agents, opacifiers and perfumes. For example, any thickening agent can be included in the formulation to adjust the viscosity of the formulation. Examples of suitable thickening agents include glycerol and xanthan gum. Some additional adjunct minor components include chalk, talc, Fullers earth, kaolin, starch, smectites clays, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, aluminium starch octenyl succinate and mixtures thereof. Amounts of these adjunct minor components may range anywhere from 0.001 up to 20% by weight of the formulation (i.e. composition).
- The delivery system can be in any form, such as a cream, a lotion, a gel, and an aerosol foam. The amount of certain adjunct minor components used in a particular formulation varies depending on the desired form of the delivery system, as would be known by a skilled artisan. For example, the amount of thickening agent used to prepare an aerosol foam formulation is about 10 to 20% of the amount used to prepare a cream formulation. Additionally, emulsifiers are added to an aerosol foam formulation, such as, for example, laureth 4.
- In another embodiment, the present invention provides a mucosal delivery system formulated to deliver a substance to, or through, a human mucous membrane without permanently disturbing the integrity of the mucous membrane. The mucous membrane is the moist tissue that lines some organs and body cavities (such as nose, mouth, lungs, rectum, stomach and vagina) and secretes mucous. The mucosal delivery system comprises the lipophilic and hydrophilic components, as described above. The particular formulations of the mucosal delivery systems are varied to accommodate the particular environment of the mucosa, as would be known by a skilled artisan.
- In a preferred embodiment, the lipophilic components of the topical or mucosal delivery system form three types of particles: gas spheres, vesicles, and lipid particles. These three types of particles are within a hydrophilic phase (i.e. aqueous medium). See
FIG. 1 . - The gas spheres are lipid monolayers that enclose air bubbles. These monolayers are formed from the lipophilic components. Negatively charged carboxylate groups stud the outer surfaces of these gas spheres. See
FIG. 2 . Preferably, these gas spheres are approximately 1 μm to approximately 500 μm in diameter. - The vesicles are lipid bilayers enclosing a hydrophilic core. These bilayers are formed from the lipophilic components. Negatively charged carboxylate groups stud the inner and outer surfaces of the vesicles. See
FIG. 3 . The vesicles can range from approximately 0.02 μm to approximately 0.5 μm in diameter. - The lipid particles are lipid monolayers enclosing fatty acids. These monolayers are formed from the lipophilic components. See
FIG. 3 . The lipid particles are less than approximately 1 to approximately 150 μm in diameter. The lipid particles may be in the form of individual lipid particles, or the lipid particles may aggregate to form crystals. - The various particles of the delivery system provide microcompartments with different properties. Due to these different microcompartments, the delivery system can be used to deliver both hydrophilic and lipophilic active substances. For example, a water soluble active substance can be located in the hydrophilic core of the vesicles, or can be located in the hydrophilic phase of the system. A lipid soluble active substance can be located within the monolayer of the gas spheres, within the bilayer of the vesicles, or within the monolayer or within the core of the lipid particles. See
FIG. 4 . - Preferably, the delivery systems comprise three phases, i.e. a foam phase, a vesicle phase and a hydrophilic phase. The foam phase comprises the gas spheres and the lipid particles. The vesicle phase comprises the vesicles and the lipid particles. The hydrophilic phase comprises water and hydrophilic components.
- In a preferred embodiment, the delivery system is produced from three portions (i.e. fractions), in particular a hydrophilic portion and two lipophilic portions. The two lipophilic portions comprise the lipophilic components as defined above. Both lipophilic portions are immersed in aqueous media. One portion is made into the foam phase. The other portion is made into the vesicle phase. The foam phase portion and the vesicle phase portion can be in a ratio from about 1:7 to about 7:1. Preferably, the foam phase portion and the vesicle phase portion are approximately equal in amount.
- Preferably, the foam phase is formed by mixing the foam phase portion at about 65 to 85° C. The pH is set to the range of about 5.5 to 8.2. The mixing is performed under conditions so as to allow gas spheres to form.
- Preferably, the vesicle phase is formed by gently mixing the vesicle phase portion at about 65 to 85° C. The pH is set to the range of about 5.5 to 8.2. After mixing, the vesicle phase portion is homogenized. Homogenization can be accomplished with, for example, a high pressure homogenizer or a sonicator. The pressure of the homogenizer can be set, for example, from about 10,000 to 40,000 psi. Preferably, the vesicle phase is produced under conditions which do not allow any gas to enter the formulation, such as in a vacuum.
- The lipid particles, and/or lipid particle crystals, form as a by-product of the formation of the foam phase and vesicle phase. In either the foam phase or vesicle phase, up to 30% of the lipophilic components can be in the form of lipid particles and/or lipid particle crystals.
- The hydrophilic phase is formed by mixing together water soluble components with water (i.e. hydrophilic portion). Examples of water soluble components include propylene glycol, glycerol, polyvinylpyrrolidone, and thickeners, e.g., xanthan gum.
- The foam phase, vesicle phase and hydrophilic phases are mixed together. Preferably, an equal amount of each phase is used in the formulation.
- The foam phase, vesicle phase and hydrophilic phases can be mixed together in any order. For example, the foam phase and the vesicle phase can be first mixed together, and then the resulting mixture can be mixed with the hydrophilic phase. As another example, the foam phase can be first mixed with the hydrophilic phase, and then the vesicle phase can be added.
- One or more active substances can be added to the foam phase portion, the vesicle phase portion, the hydrophilic portion, or a combination of these portions.
- The specific components of a formulation, and the formulation process, can be varied to obtain delivery systems which allow for different rates of the release, and degrees of penetration, of active substance(s). For example, the phase of the system in which an active substance is placed affects release and penetration rates. For instance, to enhance penetration rates of either a hydrophilic or lipophilic active substance, a major portion of the active substance is placed within the vesicle phase portion.
- Another factor which affects release and penetration rates is the size of the micro-compartments. The size of the vesicles can be controlled via the formulation process. For example, during processing, as the homogenizing pressure and duration increases, the vesicle size decreases.
- An additional factor which affects release and penetration rates is the type of phospholipids used in the formulation. For example, penetration can be enhanced by including a greater portion of unsaturated phospholipids within the formulation.
- Also, phospholipids which include elevated levels of surface active single chain agents enhance penetration. Surface active single chain agents at about a level of 2% to 10% of the phospholipids are considered to be at an elevated level. Examples of surface active agents are lysophospholipids
- An example of a phospholipid formulation comprises 95% phosphatidylcholine and 1.2% lysophosphatidylcholine. Such a formulation is sold as EPIKURON® 200 SH. A phospholipid formulation which provides enhanced penetration comprises 95% phosphatidylcholine and 3% lysophosphatidylcholine. Such a formulation is sold as EPIKURON® 200.
- The concentration of free fatty acid is also an important parameter affecting penetration rates. A relatively high level of free fatty acid enhances penetration of hydrophilic active substances.
- Penetration rates can also be enhanced by the addition of certain adjuvants. For example, an anionic surfactant can be added to the foam phase portion. Also, incorporation of glyceryidilaurate into the vesicle bilayers creates more flexible vesicles which can enhance penetration.
- Additional factors which affect release and penetration rates include: the ratio between the different lipid components; the ratio between the foam phase, the vesicle phase and the hydrophilic phase; and the ratio between the amounts of active substances within each phase.
- In one embodiment of the present invention, the lipophilic components of the delivery system form only two of the above-defined particles. That is, the formulation comprises only the gas spheres and lipid particles; or the formulation comprises only the vesicles and lipid particles.
- In this embodiment, the delivery system is produced from a hydrophilic portion and a lipophilic portion. The lipophilic portion is made either into the foam phase or the vesicle phase, as described above. Preferably, the vesicle phase is produced under conditions which do not allow any gas to enter the formulation, such as in a vacuum. The foam phase or vesicle phase is mixed with the hydrophilic phase. Preferably, an equal amount of either the foam phase or vesicle phase, and the hydrophilic phase is used in the formulation.
- Thus, while there have been described what are presently believed to be the preferred embodiments of the present invention, other and further embodiments, modifications, and improvements will be known to those skilled in the art, and it is intended to include all such further embodiments, modifications, and improvements and come within the true scope of the claims as set forth below.
- The phospholipid, cholesterol, palmitic acid and ceramide components are mixed together with water, and agitated at a temperature of 70-80° C. The following additional components are added: mevalonic acid lactone, 25-hydroxycholecalciferol, propylene glycol, glycerine, PVP, TEA added along with water, and sodium hydroxide. Sodium hydroxide is added to adjust viscosity and stabilize the formulation. Water is then added, and the formulation is agitated well. The formulation is then cooled down.
- An active substance can be dissolved in both the lipid phase and/or the water phase, depending on the solubility and concentration of the active substance.
- (An active ingredient is excluded from this formulation.)
-
Component Total amount Water 79.5% of formulation Epikuron 200SH 3.5% of formulation Palmitic acid 1.5% of formulation Cholesterol 1.5% of formulation Mevalonic acid 0.01% of formulation Triethanolamine 0.5% of formulation Phenonip 0.4% of formulation Xanthan gum 2.0% of formulation Skinflux 2.0% of formulation 25-hydroxycholecalciferol 0.0015% of formulation Propylene glycol 4.0% of formulation Glycerol 3.0% of formulation Polyvinylpyrrolidone 2.0% of formulation Epikuron 200SH are hydrogenated lecithins, i.e. phosphatidylcholine (PC). “Skinflux” is a blend product obtainable from Degussa Goldschmidt which contains: Ceramide 1, 3, 6II; Phytosphingosine; Cholesterol; Sodium Lauroyl Lactylate; Carbomer; and Xanthan Gum. Mevalonic acid lactone is a lipid precursor for cholesterol/fatty acids. 25-Hydroxycholecalciferol is a lipid precursor for ceramides Xanthan Gum is a thickener (polysaccharide). PHENONIP ® is a preservative and a blend of parabens. - Three fractions, a vesicle fraction, a foam fraction and a hydrophilic fraction, are first prepared separately, as described below. Each fraction weighs 3.3 kg. Then the three fractions are mixed together. The following tables show the percent amount of each component contributed by each fraction to the final formulation. Thus, for each component, the sum of the percent amounts of all the fractions is 100%.
-
-
Percent Amount in Final Component Formulation Water 33% of total water Hydrogenated lecithins 50% of total amount Palmitic acid 50% of total amount Cholesterol 50% of total amount Mevalonic acid 50% of total amount Triethanol amine 50% of total amount Preservative (e.g., Paraben mixture) 50% of total amount Xanthan gum 15% of total amount Skinflux 33% of total amount 25-hydroxycholecalciferol 50% of total amount 5M sodium hydroxide 1.3 ml per 1000 grams of water The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the vesicle fraction to the final formulation. - In forming the vesicle fraction, the components are mixed and heated to the temperature range of 65 to 85° C. while gently stirring. The pH is set to the range of 5.5 to 8.2 by the use of sodium hydroxide. The resulting mixture is then homogenized. Homogenization can be accomplished by, for example, a homogenizer set at a high pressure (e.g. 10,000 to 40,000 psi); or by a sonicator. The size of the vesicles is partially dependent upon how long the resulting mixture is agitated. For example, to obtain an average vesicle size of 0.140 μm, the resulting mixture is agitated for 60 minutes at about 70° C. The mixture is then allowed to cool to below 40° C.
-
-
Percent Amount in Final Component Formulation Water 33% of total water Hydrogenated lecithins 50% of total amount Palmitic acid 50% of total amount Cholesterol 50% of total amount Mevalonic acid 50% of total amount Triethanol amine 50% of total amount Preservative (e.g. a paraben mixture) 50% of total amount Xanthan gum 7.5% of total amount Skinflux 33% of total amount 25-hydroxycholecalciferol 50% of total amount 5M sodium hydroxide 1.3 ml per 1000 g of water The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the foam fraction to the final formulation. - In forming the foam fraction, the components are mixed and heated to the temperature range of 65 to 85° C. while stirring. The pH is set to the range of 5.5 to 8.2 by the use of sodium hydroxide. The composition is mixed vigorously for 1 minute. Mixing can be done with ULTRATURRAX® from IKA Werke, Janke & Kunkel GmbH & Co KG (Staufen, Germany). The composition is then allowed to cool to below 40° C.
-
-
Percent Amount in Final Component Formulation Water 34% of total water Propylene glycol 100% of total amount Glycerol 100% of total amount Polyvinylpyrrolidone 100% of total amount Xanthan gum 77.5% of total amount Skinflux 34% of total amount 5M sodium hydroxide 3.0 ml per 1000 g of water The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the hydrophilic fraction to the final formulation. - In forming the hydrophilic fraction, the components are mixed and heated to the temperature range of 65 to 85° C. while stirring. The pH is set to the range of 5.5 to 8.2 by use of sodium hydroxide. Once homogeneous, the composition is then allowed to cool to below 40° C.
- In forming the final formulation, after all the fractions are cooled down (below 40° C.), the three fractions are mixed together in any order. For example, the foam fraction is added to the vesicle fraction and gently mixed. Then the hydrophilic fraction is added. The resulting mixture is gently blended for several minutes to obtain a homogeneous solution.
- The delivery system of this example is in the form of a cream. In order to produce a delivery system in an aerosol foam form, the total amount of xanthan gum in the final formulation is reduced from 2% to about 0.3%. Additionally, an emulsifier is added, such as laureth 4. Preferably, the emulsifier makes up about 0.7% of the final formulation.
- An example of a 48 kg batch of a formulation of the delivery system follows. The three fractions used to prepare this formulation each contain 16 kg.
-
INCI Name Trade Name Supplier CAS Amount Hydrogenated Epikuron 200 SH Degussa 1.7 kg Lecithines Goldschmidt Cholesterol Vendico 57-88-5 0.8 kg Palmitic acid Karlshamn 57-10-3 0.8 kg Ceramide 1, 3, 6II, Skin Flux Degussa 1.0 kg Phytosphingosine, Goldschmidt Cholesterol, Sodium Lauroyl Lactylate, Carbomer, Xanthan Gum. Mevalonic acid Sigma Aldrich 674-26-0 4.8 g lactone 25-Hydroxy- Solvay 19356-17-3 0.72 kg cholecalciferol Propylene glycol MB-Sveda 57-55-6 2.0 kg Glycerin, 99.5% Vendico 56-81-5 1.5 kg Polyvinylpyrrolidone Apoteket 9003-39-8 1.0 kg Xanthan gum Sigma Aldrich 11138-66-2 1.0 kg Triethanolamine, MB-Sveda 102-71-6 0.3 kg 85% Phenonip Vendico 0.2 kg Chemical Lidocain USP-grade Apoteket 2.4 kg Purified Up to Water 48 kg - In the present context enhancing skin barrier restoration can be measured by tape and/or acetone striping of stratum corneum skin lipid content before, during and after a treatment period with the present invention and other systems. Then HPLC analysis of skin lipid content of stratum corneum is conducted.
Claims (80)
1. A water-based topical delivery system for an active substance, capable of enhancing skin barrier restoration in the stratum corneum comprising water; fatty acids; cholesterol; and a ceramide/phospholipid portion.
2. A delivery system according to claim 1 wherein the ratio of ceramide/phospholipid portion:cholesterol:fatty acid is approximately between 2:1:1 and 2.35:1:1.
3. A delivery system according to claim 1 further comprising at least one skin lipid precursor.
4. A delivery system according to claim 3 wherein the fatty acid is between 0.5-10%; the cholesterol is between 0.5-10%; the lipid precursors are between 0.000001-10%; and the ceramide/phospholipid portion is between 0.005-20%.
5. A delivery system according to claim 1 wherein the fatty acid comprises ten to twenty-four carbon atoms.
6. A delivery system according to claim 5 wherein the fatty acid comprises sixteen to eighteen carbon atoms.
7. A delivery system according to claim 1 wherein the fatty acid is lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, oleic acid, palmitoleic acid, linoleic acid, linolenic acid, arachidonic acid, precursors thereof, and/or unsaturated derivatives thereof, and/or mixtures thereof.
8. A delivery system according to claim 1 , wherein said fatty acid is selected from a group consisting of linoleic acid, γ-linolenic acid, homo-γ-linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid, timnodonic acid, hexaenoic acid and mixtures thereof.
9. A delivery system according to claim 6 wherein the ceramide is ceramide 1, ceramide 3, ceramide 4, ceramide 5, ceramide 6A, a cerebroside, ceramide 6B, a pseudoceramide, a neoceramide, or mixtures thereof.
10. A delivery system according to claim 9 wherein the pseudoceramide is
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)heptanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxyoctadecyl)-N-(2-O-glucopyranosyl)ethylpentanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)hexanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2butylhexanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2-hydroxyhexanamide;
N-(2-hydroxytetraadecyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyhexadecyl)-N-(2-sulfoethyl)hexadecanamide;
N-(2-hydroxyoctadecyl)-N-(2-phosphoethyl)butanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-nonanyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-sulfohydroxyethyl)decanamide;
N-(2-hydroxy-3-decyloxypropyl)-N-(2-hydroxyethyl)hexanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)co-o-linoleoyldocosanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)-2-methylpropanamide;
N-(2-hydroxy-3-tetraadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)heptanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-phosphoethyl)hexadecanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-)-glucopyranosyl)ethyl-2-hydroxypropanamide; or N-(2-hydroxy-3-octyloxypropyl)-N-(2-hydroxyethyl)pentanamide.
11. A delivery system according to claim 9 wherein the neoceramide is:
N-(2,3-dihydroxypropyl)-N-(hexadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(tetradecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxypropanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(2-ethylhexadecyl)hexanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyoctanamide;
N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyhexanamide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)octanamide;
N-(2-hydroxy-3-phosphopropyl)-N-(octadecyl)ethanamide;
N-(2-hydroxy-3-sulfopropyl)-N-(hexadecyl)butanamide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)decanamide;
N-(2,3-dihydroxypropyl)-N-(heptadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(6-dodecenyl)hexadecan-amide;
N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxy-ethanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)2-hydroxypropan-amide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(heptadecyl)-ethanamide;
N-(2-hydroxy-3-sulfopropyl)-N-(dodecyl)heptanamide;
N-(2,3-dihydroxypropyl)-N-(tetradecyl)-4-hydroxybutan-amide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-(t)-O-linoleoyl-docosanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxy-heptan-amide;
N-(2,3-dihydroxypropyl)-N-iyiodecyl)-(t)-O-linoleoyldocosanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-3-hydroxybutanamide;
N-(2-phospho-3hydroxypropyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(2-methylheptadecyl)propanamide;
N-(2,3-dihydroxypropyl)-N-(3-ethylheptadecyl)butanamide;
N-(2-sulfo-3-hydroxypropyl)-N-(1-octadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)propanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)decanamide;
N-(2,3-dihydroxypropyl)-N-(3-ethyldodecyl)butanamide;
N-(2-O-glucopyranosyl-3-hydroxy propyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxypropanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxyheptanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)-2-hydroxyoctanamide;
N-(2,3-dihydroxypropyl)-N(hexadecyl)-2-methylheptanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypentanamide;
N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxyheptanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxypropanamide; or
N-(2; 3-dihydroxypropyl)-N-(tetradecyl)ethanamide.
12. A delivery system according to claim 1 , wherein said phospholipid is selected from a group consisting of phosphatidylcholine, DSPC 18, phosphatidic acid, inositol phosphate, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine and mixtures thereof.
13. A delivery system according to claim 12 , wherein said phospholipid comprises at least one lysophospholipid.
14. A delivery system according to claim 13 wherein the lysophospholipid is selected from the group consisting of monopalmitoylphosphatidylcholine (MPPC), lysophosphatidylcholines, lysophosphatidylglycerols, lysophosphatidylethanolamines, lysophosphatidylinositols, lysophosphatidylserines, lysophosphatidic acid, and mixtures thereof.
15. A delivery system according to claim 3 wherein the lipid precursor comprises mevalonic acid or 25-hydroxycholecalciferol.
16. A delivery system according to claim 3 wherein the lipid precursor comprises deoxyacetein cimifugoside, adapalene, adenosine, aloe derived lectins, 3-aminopropyl dihydrogen phosphate, anise extracts, ascorbic acid and derivatives thereof, ascorbyl palmitate, asiatic acid, benzoic acid derivatives, biotin, butanoyl betulinic acid, cathecholamines, coenzyme Q10, dehydrocholesterol, dehydroascorbic acid and derivatives thereof, estrogen and derivatives, eythrobic acid, genistein, lipoic acid, 4-methoxy salicylic acid, N-acetyl cysteine, panthetine, pregnenolone and derivatives, retinal, retinoates, retinal, retinyl acetate, retinyl glucuronate, retinyl linoleate, retinyl palmitate, retinyl proprionate, phytosphingosine, or sphingosine.
17. A delivery system according to claim 1 further comprising triethanolamine.
18. A delivery system according to claim 1 , wherein the water content exceeds 50%.
19. A delivery system according to claim 1 , wherein the water content exceeds 75%.
20. A delivery system according to claim 1 , wherein the water content exceeds 79%.
21. A delivery system according to claim 1 , wherein the water content exceeds 90%.
22. A delivery system according to claim 3 , wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 2-20%.
23. A delivery system according to claim 3 , wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 5-20%.
24. A delivery system according to claim 3 , wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 5-15%.
25. A delivery system according to claim 3 , wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 6-13%.
26. A delivery system according to claim 3 , comprising a combination of:
27. A delivery system according to claim 26 wherein the lipid precursor is mevalonic acid.
28. A delivery system according to claim 26 , further comprising
29. A delivery system according to claim 26 , further comprising
30. A delivery system according to claim 26 , wherein the lipid precursor comprises 0.01% of Mevalonic acid, 0.0015% 25-Hydroxycholecalciferol, or a combination of Mevalonic acid, and 25-Hydroxycholecalciferol.
31. A delivery system according to claim 3 , wherein said skin barrier restoration is enhanced by in situ promotion of cholesterol synthesis in the stratum corneum.
32. A delivery system according to claim 3 , wherein said skin barrier restoration is enhanced by in situ promotion of ceramide synthesis in the stratum corneum.
33. A delivery system according to claim 3 , wherein said skin barrier restoration is enhanced by in situ promotion of sphingolipid synthesis in the stratum corneum.
34. A delivery system according to claim 1 , wherein said system further comprises one or more therapeutically active substances selected from the group consisting of peptides, proteins, sunscreens, tanning agents, skin anti-wrinkling agents, anti-dandruff agents, anti-acne agents, hair growth stimulants, hormones, vaccines, nicotine, interferon, pain killers, vitamins; and substances which treat eczema, dry skin, itchy skin, fungal infections, acne, skin cancer, hair loss, louse infections, psoriasis, and skin lesions.
35. A delivery system according to claim 3 , wherein the lipids of said system blend with the lipids present in the cornea stratum, resulting in a temporary and reversible atrophy in the lipid bilayer, thereby enhancing possibility for penetration of therapeutic substances delivered by the system.
36. A delivery system according to claim 3 , wherein the system does not comprise alcohol.
37. A delivery system according to claim 36 , wherein the alcohol is ethanol.
38. A delivery system according to claim 3 , wherein the system comprises less than 10% alcohol.
39. A delivery system according to claim 38 wherein the alcohol is ethanol.
40. A topical delivery system for an active substance comprising water and lipophilic components, wherein the lipophilic components comprise fatty acids, cholesterol, and a ceramide/phospholipid portion, and wherein the lipophilic components are in the form of lipid particles, and gas spheres or vesicles.
41. A topical delivery system according to claim 40 further comprising at least one skin lipid precursor.
42. A topical delivery system for an active substance comprising water and lipophilic components, wherein the lipophilic components comprise fatty acids, cholesterol, and a ceramide/phospholipid portion, and wherein the lipophilic components are in the form of lipid particles, gas spheres and vesicles.
43. A topical delivery system according to claim 42 further comprising at least one skin lipid precursor.
44. A topical delivery system according to claim 40 wherein the diameter of the gas spheres is approximately 1 μm to 500 μm.
45. A topical delivery system according to claim 40 wherein the diameter of the vesicles is approximately 0.02 μm to 0.5 μm.
46. A topical delivery system according to claim 40 wherein the diameter of the lipid particles is approximately less than 1 μm to 150 μm.
47. A delivery system according to claim 41 wherein the fatty acid is between 0.5-10%; the cholesterol is between 0.5-10%; the lipid precursors are between 0.000001-10%; and the ceramide/phospholipid portion is between 0.005-20%.
48. A delivery system according to claim 40 wherein the fatty acid comprises ten to twenty-four carbon atoms.
49. A delivery system according to claim 48 wherein the fatty acid comprises sixteen to eighteen carbon atoms.
50. A delivery system according to claim 40 wherein the fatty acid is lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, oleic acid, palmitoleic acid, linoleic acid, linolenic acid, arachidonic acid, precursors thereof, and/or unsaturated derivatives thereof, and/or mixtures thereof.
51. A delivery system according to claim 40 , wherein said fatty acid is selected from a group consisting of linoleic acid, γ-linolenic acid, homo-γ-linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid, timnodonic acid, hexaenoic acid and mixtures thereof.
52. A delivery system according to claim 43 wherein the ceramide is ceramide 1, ceramide 3, ceramide 4, ceramide 5, ceramide 6A, a cerebroside, ceramide 6B, a pseudoceramide, a neoceramide, or mixtures thereof.
53. A delivery system according to claim 52 wherein the pseudoceramide is
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)heptanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxyoctadecyl)-N-(2-O-glucopyranosyl)ethylpentanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)hexanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2butylhexanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2-hydroxyhexanamide;
N-(2-hydroxytetraadecyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyhexadecyl)-N-(2-sulfoethyl)hexadecanamide;
N-(2-hydroxyoctadecyl)-N-(2-phosphoethyl)butanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-nonanyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-sulfohydroxyethyl)decanamide;
N-(2-hydroxy-3-decyloxypropyl)-N-(2-hydroxyethyl)hexanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)co-o-linoleoyldocosanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)-2-methylpropanamide;
N-(2-hydroxy-3-tetraadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)heptanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-phosphoethyl)hexadecanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-)-glucopyranosyl)ethyl-2-hydroxypropanamide; or N-(2-hydroxy-3-octyloxypropyl)-N-(2-hydroxyethyl)pentanamide.
54. A delivery system according to claim 52 wherein the neoceramide is:
N-(2,3-dihydroxypropyl)-N-(hexadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(tetradecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxypropanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(2-ethylhexadecyl)hexanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyoctanamide;
N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyhexanamide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)octanamide;
N-(2-hydroxy-3-phosphopropyl)-N-(octadecyl)ethanamide;
N-(2-hydroxy-3-sulfopropyl)-N-(hexadecyl)butanamide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)decanamide;
N-(2,3-dihydroxypropyl)-N-(heptadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(6-dodecenyl)hexadecan-amide;
N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxy-ethanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypropan-amide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(heptadecyl)-ethanamide;
N-(2-hydroxy-3-sulfopropyl)-N-(dodecyl)heptanamide;
N-(2,3-dihydroxypropyl)-N-(tetradecyl)-4-hydroxybutan-amide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-(t)-O-linoleoyl-docosanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxy-heptan-amide;
N-(2,3-dihydroxypropyl)-N-iyiodecyl)-(t)-O-linoleoyldocosanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-3-hydroxybutanamide;
N-(2-phospho-3hydroxypropyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(2-methylheptadecyl)propanamide;
N-(2,3-dihydroxypropyl)-N-(3-ethylheptadecyl)butanamide;
N-(2-sulfo-3-hydroxypropyl)-N-(1-octadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)propanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)decanamide;
N-(2,3-dihydroxypropyl)-N-(3-ethyldodecyl)butanamide;
N-(2-O-glucopyranosyl-3-hydroxy propyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxypropanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxyheptanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)-2-hydroxyoctanamide;
N-(2,3-dihydroxypropyl)-N(hexadecyl)-2-methylheptanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypentanamide;
N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxyheptanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxypropanamide; or
N-(2; 3-dihydroxypropyl)-N-(tetradecyl)ethanamide.
55. A delivery system according to claim 40 , wherein said phospholipid is selected from a group consisting of phosphatidylcholine, DSPC 18, phosphatidic acid, inositol phosphate, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine and mixtures thereof.
56. A delivery system according to claim 55 , wherein the phospholipids comprises at least one lysophospholipid.
57. A delivery system according to claim 56 wherein the lysophospholipid is selected from the group consisting of monopalmitoylphosphatidylcholine (WPC), lysophosphatidylcholines, lysophosphatidylglycerols, lysophosphatidylethanolamines, lysophosphatidylinositols, lysophosphatidylserines, lysophosphatidic acid, and mixtures thereof.
58. A delivery system according to claim 41 wherein the lipid precursor comprises mevalonic acid or 25-hydroxycholecalciferol.
59. A delivery system according to claim 41 wherein the lipid precursor comprises deoxyacetein cimifugoside, adapalene, adenosine, aloe derived lectins, 3-aminopropyl dihydrogen phosphate, anise extracts, ascorbic acid and derivatives thereof, ascorbyl palmitate, asiatic acid, benzoic acid derivatives, biotin, butanoyl betulinic acid, cathecholamines, coenzyme Q10, dehydrocholesterol, dehydroascorbic acid and derivatives thereof, estrogen and derivatives, eythrobic acid, genistein, lipoic acid, 4-methoxy salicylic acid, N-acetyl cysteine, panthetine, pregnenolone and derivatives, retinal, retinoates, retinal, retinyl acetate, retinyl glucuronate, retinyl linoleate, retinyl palmitate, retinyl proprionate, phytosphingosine, or sphingosine.
60. A delivery system according to claim 40 further comprising triethanolamine.
61. A delivery system according to claim 40 , wherein the water content exceeds 50%.
62. A delivery system according to claim 40 , wherein the water content exceeds 75%.
63. A delivery system according to claim 40 , wherein the water content exceeds 79%.
64. A delivery system according to claim 40 , wherein the water content exceeds 90%.
65. A delivery system according to claim 40 , wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 2-20%.
66. A delivery system according to claim 41 , wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 5-20%.
67. A delivery system according to claim 41 , wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 5-15%.
68. A delivery system according to claim 41 , wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 6-13%.
69. A delivery system according to claim 41 , comprising a combination of:
70. A delivery system according to claim 69 wherein the lipid precursor is mevalonic acid.
71. A delivery system according to claim 69 , further comprising
72. A delivery system according to claim 69 , wherein the lipid precursor comprises 0.01% of Mevalonic acid; 0.0015% of 25-Hydroxycholecalciferol or a mixture of both.
73. A delivery system according to claim 41 , wherein said skin barrier restoration is enhanced by in situ promotion of cholesterol synthesis in the stratum corneum.
74. A delivery system according to claim 41 , wherein said skin barrier restoration is enhanced by in situ promotion of ceramide synthesis in the stratum corneum.
75. A delivery system according to claim 41 , wherein said skin barrier restoration is enhanced by in situ promotion of sphingolipid synthesis in the stratum corneum.
76. A delivery system according to claim 40 , wherein said system further comprises one or more therapeutically active substances selected from the group consisting of: peptides, proteins, sunscreens, tanning agents, skin anti-wrinkling agents, anti-dandruff agents, anti-acne agents, hair growth stimulants, hormones, vaccines, nicotine, interferon, pain killers, vitamins; and substances which treat eczema, dry skin, itchy skin, fungal infections, acne, skin cancer, hair loss, louse infections, psoriasis, and skin lesions.
77. A delivery system according to claim 40 , wherein the system does not comprise alcohol.
78. A delivery system according to claim 77 , wherein the alcohol is ethanol.
79. A delivery system according to claim 40 , wherein the system comprises less than 10% alcohol.
80. A delivery system according to claim 79 wherein the alcohol is ethanol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/082,406 US20090081139A1 (en) | 2002-03-13 | 2008-04-09 | Water-based delivery systems |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36505902P | 2002-03-13 | 2002-03-13 | |
US10/388,371 US20040009213A1 (en) | 2002-03-13 | 2003-03-13 | Water-based delivery systems |
US12/082,406 US20090081139A1 (en) | 2002-03-13 | 2008-04-09 | Water-based delivery systems |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/388,371 Continuation US20040009213A1 (en) | 2002-03-13 | 2003-03-13 | Water-based delivery systems |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090081139A1 true US20090081139A1 (en) | 2009-03-26 |
Family
ID=28042008
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/388,371 Abandoned US20040009213A1 (en) | 2002-03-13 | 2003-03-13 | Water-based delivery systems |
US12/082,406 Abandoned US20090081139A1 (en) | 2002-03-13 | 2008-04-09 | Water-based delivery systems |
US12/290,455 Expired - Lifetime US8029810B2 (en) | 2002-03-13 | 2008-10-30 | Water-based delivery systems |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/388,371 Abandoned US20040009213A1 (en) | 2002-03-13 | 2003-03-13 | Water-based delivery systems |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/290,455 Expired - Lifetime US8029810B2 (en) | 2002-03-13 | 2008-10-30 | Water-based delivery systems |
Country Status (9)
Country | Link |
---|---|
US (3) | US20040009213A1 (en) |
EP (1) | EP1534213B1 (en) |
JP (1) | JP4806519B2 (en) |
KR (1) | KR101076335B1 (en) |
AU (1) | AU2003233396B2 (en) |
CA (1) | CA2476859C (en) |
ES (1) | ES2411656T3 (en) |
NZ (1) | NZ534377A (en) |
WO (1) | WO2003077861A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090226491A1 (en) * | 2002-03-13 | 2009-09-10 | Thomas Skold | Water-based delivery systems |
US10406088B2 (en) | 2015-01-20 | 2019-09-10 | TetraDerm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2855049B1 (en) * | 2003-05-19 | 2006-07-21 | Oreal | COMPOSITION COMPRISING A 6-HYDROXY SPHINGENINE CERAMIDE PRECURSOR AND A 6-HYDROXYLASE PATH ACTIVATOR FOR USE IN ENHANCING THE BARRIER FUNCTION OF THE SKIN |
FR2855047B1 (en) * | 2003-05-19 | 2007-11-30 | Oreal | COMPOSITION COMPRISING A SPHINGOID BASE, AN ACTIVATOR OF THE 4-AND / OR 6-HYDROXYLASE PATHWAY AND A FATTY ACID, USE FOR ENHANCING THE BARRIER FUNCTION OF THE SKIN |
FR2855048B1 (en) * | 2003-05-19 | 2006-07-21 | Oreal | COMPOSITION COMPRISING A PHYTOSPHINGOSIN-BASED CERAMIDE PRECURSOR AND AN ACTIVATOR OF THE 4-HYDROXYLASE PATHWAY, USE FOR ENHANCING THE BARRIER FUNCTION OF THE SKIN |
WO2006133829A2 (en) * | 2005-06-17 | 2006-12-21 | Dsm Ip Assets B.V. | Use of 25-hydroxy-vitamin d3 |
US20070154403A1 (en) * | 2006-01-05 | 2007-07-05 | Thomas Skold | Oral, Pulmonary and Transmucosal Delivery Composition |
FR2901701B1 (en) * | 2006-05-31 | 2010-10-29 | Galderma Res & Dev | COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID DERIVATIVE AND AT LEAST ONE FILMOGENIC AGENT, PROCESSES FOR THEIR PREPARATION, AND USES THEREOF |
EP2062574B1 (en) * | 2006-09-08 | 2015-03-25 | Kaneka Corporation | Composition comprising reduced coenzyme q10 and lysolecithin |
JP5196833B2 (en) * | 2007-04-07 | 2013-05-15 | ヤヱガキ醗酵技研株式会社 | Functional food ingredients and production methods |
JP2009143897A (en) * | 2007-11-19 | 2009-07-02 | Neochemir Inc | Therapeutic agent for pimple |
WO2009101412A1 (en) * | 2008-02-13 | 2009-08-20 | Cipla Limited | Topical pharmaceutical composition |
KR20120129864A (en) | 2009-08-21 | 2012-11-28 | 타겟티드 딜리버리 테크놀러지스 리미티드 | Vesicular formulations |
US8846723B2 (en) | 2010-07-29 | 2014-09-30 | Eastman Chemical Company | Esters of O-substituted hydroxy carboxylic acids and preparations thereof |
US8613940B2 (en) | 2010-09-03 | 2013-12-24 | Eastman Chemical Company | Carbonate derivatives as skin care |
US9163296B2 (en) | 2011-01-25 | 2015-10-20 | Tenaris Coiled Tubes, Llc | Coiled tube with varying mechanical properties for superior performance and methods to produce the same by a continuous heat treatment |
IT1403689B1 (en) | 2011-02-07 | 2013-10-31 | Dalmine Spa | HIGH-RESISTANCE STEEL TUBES WITH EXCELLENT LOW TEMPERATURE HARDNESS AND RESISTANCE TO CORROSION UNDER VOLTAGE SENSORS. |
US8329938B2 (en) * | 2011-02-21 | 2012-12-11 | Eastman Chemical Company | Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
US9803256B2 (en) | 2013-03-14 | 2017-10-31 | Tenaris Coiled Tubes, Llc | High performance material for coiled tubing applications and the method of producing the same |
EP2789700A1 (en) | 2013-04-08 | 2014-10-15 | DALMINE S.p.A. | Heavy wall quenched and tempered seamless steel pipes and related method for manufacturing said steel pipes |
CN105452515A (en) | 2013-06-25 | 2016-03-30 | 特纳瑞斯连接有限责任公司 | High-chromium heat-resistant steel |
JP2016523903A (en) * | 2013-07-01 | 2016-08-12 | ネオファーム シーオー., エルティーディー.Neopharm Co., Ltd. | Multilayer emulsified transdermal drug delivery system |
GB201313735D0 (en) * | 2013-07-31 | 2013-09-11 | Pro Bono Internat Trading Ltd | Vesicles |
KR20210116701A (en) * | 2013-07-31 | 2021-09-27 | 시퀘솜 네크놀로지 홀딩스 리미티드 | Vesicles |
KR101509582B1 (en) * | 2013-10-30 | 2015-04-14 | 한국콜마주식회사 | COSMETIC COMPOSITION WITH ANTI-INFLAMMATORY IMPROVEMENT AND MOISTURIZING EFFECT CONTAINING γ-LINOLENIC ACID |
WO2015072564A1 (en) * | 2013-11-17 | 2015-05-21 | 株式会社メドレックス | Transdermal colloidal solution agent |
WO2015095010A2 (en) * | 2013-12-18 | 2015-06-25 | International Flora Technologies, Ltd. | Human sebum mimetics derived from botanical sources and methods for making the same |
JP6356446B2 (en) * | 2014-03-14 | 2018-07-11 | 富士フイルム株式会社 | Ceramide dispersion composition |
KR101455684B1 (en) * | 2014-04-29 | 2014-11-04 | 주식회사 씨엠에스랩 | Emulsion type-cosmetic composition containing liquid crystal for improvement of skin barrier and skin regeneration effect |
DK3316857T3 (en) | 2015-06-30 | 2021-10-18 | Sequessome Tech Holdings Limited | MULTIFASIC COMPOSITIONS |
US10137073B2 (en) * | 2016-01-02 | 2018-11-27 | L'oreal | Cosmetic compositions comprising ceramides and cholesterol |
KR101750238B1 (en) * | 2016-04-27 | 2017-06-27 | (주)네오팜 | Compositions for anti-aging |
KR101752312B1 (en) * | 2016-11-22 | 2017-06-29 | 주식회사 씨엠에스랩 | Vesicles containing Saccharide isomerate, Hydrolyzed lupine protein and Intercorneocyte lipid mimetics, and Composition for Skin external application comprising the same |
WO2018123003A1 (en) * | 2016-12-28 | 2018-07-05 | 小林製薬株式会社 | Topical composition for suppressing melanogenesis |
KR101910962B1 (en) * | 2017-01-05 | 2018-10-24 | 주식회사 마크로케어 | Ceramide liquid crystal composition and Preparation Method Thereof |
US10434554B2 (en) | 2017-01-17 | 2019-10-08 | Forum Us, Inc. | Method of manufacturing a coiled tubing string |
RU2746414C1 (en) * | 2017-05-23 | 2021-04-13 | ТиСиАй КО., ЛТД. | Emulsified liposomal composition and method for its preparation |
KR102485259B1 (en) | 2018-03-27 | 2023-01-06 | (주)아모레퍼시픽 | Liquid lipid composite composition for improving hair condition |
KR102078667B1 (en) * | 2018-06-18 | 2020-02-19 | 주식회사 고운세상코스메틱 | Cosmetic composition containg nanoemulsion encapsulated with 7-dehydrocholesterol, cholesterol and stearic acid in inner phase of hyaluronate-ceramide NP complex and manufacturing method thereof |
CN115243666A (en) | 2020-03-09 | 2022-10-25 | 高砂香料工业株式会社 | Ceramide proliferation promoter |
JP7406057B2 (en) * | 2021-03-03 | 2023-12-27 | 東洋ビューティ株式会社 | External microparticle capsule preparations and skin external preparations |
US12005135B2 (en) | 2021-05-28 | 2024-06-11 | Mary Kay Inc. | Barrier guard technology |
EP4353328A3 (en) | 2022-10-15 | 2024-05-22 | LCS Advanced Solutions, LLC | Structurally diverse, stable, and radiation-protective particle matrix sunscreen and cosmetic compositions and related methods |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4508703A (en) * | 1982-02-17 | 1985-04-02 | Parfums Christian Dior | Production of pulverulent mixtures of lipidic and hydrophobic constituents |
US5196190A (en) * | 1990-10-03 | 1993-03-23 | Zenith Technology Corporation, Limited | Synthetic skin substitutes |
US5206020A (en) * | 1991-01-15 | 1993-04-27 | Elizabeth Arden Company, Division Of Conopco, Inc. | Synthetic pseudoceramide and cosmetic compositions thereof |
US5468475A (en) * | 1992-11-17 | 1995-11-21 | Pola Chemical Industries Inc. | Cosmetic composition with choline derivative |
US5534499A (en) * | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
US5631012A (en) * | 1994-09-02 | 1997-05-20 | Shanni; David | Cosmetic preparations for moisturizing human skin containing specific lipids |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5776480A (en) * | 1994-12-14 | 1998-07-07 | L'oreal | Cosmetic or dermatological composition containing a mixture of ceramides for moisturizing the skin |
US5817856A (en) * | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5993830A (en) * | 1997-01-17 | 1999-11-30 | Ponsus Ab | Cosmetic skin preparation |
US6153209A (en) * | 1999-09-28 | 2000-11-28 | The Procter & Gamble Company | Article having a transferable breathable skin care composition thereon |
US6497888B1 (en) * | 1999-10-14 | 2002-12-24 | L'ORéAL S.A. | Process for limiting the penetration into the skin and/or the keratinous fibres of an active cosmetic and/or pharmaceutical agent |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6730288B1 (en) * | 1998-09-11 | 2004-05-04 | Connetics Australia Pty Ltd | Mousse composition |
US6824785B1 (en) * | 2000-02-09 | 2004-11-30 | C. Neil Kitson | Skin treatment composition and methods of use |
US6932963B2 (en) * | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4568703A (en) * | 1984-07-27 | 1986-02-04 | Bp Chemicals Limited | Process for the production of polymers containing isocyanurate and or oxazolidone linkages |
JPS62169711A (en) * | 1986-01-22 | 1987-07-25 | Shiseido Co Ltd | Skin cosmetic |
US5320906A (en) * | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
US5628936A (en) * | 1987-03-13 | 1997-05-13 | Micro-Pak, Inc. | Hybrid paucilamellar lipid vesicles |
JPH0720857B2 (en) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
JP3765579B2 (en) * | 1990-08-24 | 2006-04-12 | イーデーエーアー アーゲー | Ultra-fine droplet preparation for active substance administration |
US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
US5298246A (en) * | 1991-01-09 | 1994-03-29 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Stable pharmaceutical composition and method for its production |
ATE192928T1 (en) * | 1992-06-19 | 2000-06-15 | Univ California | LIPIDS FOR EPIDERMAL MOISTURIZATION AND RESTORING BARRIER FUNCTION |
EP0711558A1 (en) | 1994-10-21 | 1996-05-15 | Unilever Plc | Compositions for topical application to skin, hair and nails |
EP0789584B1 (en) * | 1994-11-04 | 2001-09-19 | Polymun Scientific Immunbiologische Forschung GmbH | Application of superoxide dismutase in liposomes |
DE4439815C2 (en) | 1994-11-08 | 2001-06-07 | Mann & Hummel Filter | Filters, in particular liquid filters |
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
WO1996037192A1 (en) * | 1995-05-26 | 1996-11-28 | Vesifact Ag | Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
IN184589B (en) * | 1996-10-16 | 2000-09-09 | Alza Corp | |
WO1998017253A1 (en) * | 1996-10-23 | 1998-04-30 | The Regents Of The University Of California | Method and compositions for disrupting the epithelial barrier function |
IT1292142B1 (en) * | 1997-06-12 | 1999-01-25 | Maria Rosa Gasco | PHARMACEUTICAL COMPOSITION IN THE FORM OF SOLID LIPID MICROPARTICLES SUITABLE FOR PARENTERAL ADMINISTRATION |
IT1296914B1 (en) * | 1997-12-01 | 1999-08-03 | Maria Rosa Gasco | PHARMACEUTICAL COMPOSITION INCLUDING MICROPARTICLES SUITABLE FOR TRANSMUCOSAL PASSAGE AND OVERCOMING THE BARRIER |
ES2226203T3 (en) * | 1998-12-23 | 2005-03-16 | Idea Ag | IMPROVED FORMULATION FOR NON-INVASIVE TOPICAL APPLICATION. |
DE19923246A1 (en) | 1999-05-20 | 2000-12-07 | Tyco Electronics Logistics Ag | Ferrule for an optical fiber and method for attaching the ferrule to the optical fiber |
KR19990078610A (en) * | 1999-07-03 | 1999-11-05 | 김현준 | Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin |
MXPA02000053A (en) * | 1999-07-05 | 2003-07-21 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers. |
KR100371491B1 (en) * | 1999-07-27 | 2003-02-07 | 주식회사 두산 | Cream Composition For Skin Care |
KR101076335B1 (en) * | 2002-03-13 | 2011-10-26 | 토마스 스쾰트 | Water-based delivery systems |
US20050129722A1 (en) * | 2002-03-13 | 2005-06-16 | Collagenex Pharmaceuticals, Inc. | Water-based delivery systems |
US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
-
2003
- 2003-03-13 KR KR1020047014070A patent/KR101076335B1/en active IP Right Grant
- 2003-03-13 NZ NZ534377A patent/NZ534377A/en not_active IP Right Cessation
- 2003-03-13 WO PCT/US2003/007752 patent/WO2003077861A2/en active IP Right Grant
- 2003-03-13 CA CA2476859A patent/CA2476859C/en not_active Expired - Lifetime
- 2003-03-13 US US10/388,371 patent/US20040009213A1/en not_active Abandoned
- 2003-03-13 JP JP2003575915A patent/JP4806519B2/en not_active Expired - Fee Related
- 2003-03-13 EP EP03728242.3A patent/EP1534213B1/en not_active Expired - Lifetime
- 2003-03-13 AU AU2003233396A patent/AU2003233396B2/en not_active Ceased
- 2003-03-13 ES ES03728242T patent/ES2411656T3/en not_active Expired - Lifetime
-
2008
- 2008-04-09 US US12/082,406 patent/US20090081139A1/en not_active Abandoned
- 2008-10-30 US US12/290,455 patent/US8029810B2/en not_active Expired - Lifetime
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4508703A (en) * | 1982-02-17 | 1985-04-02 | Parfums Christian Dior | Production of pulverulent mixtures of lipidic and hydrophobic constituents |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5196190A (en) * | 1990-10-03 | 1993-03-23 | Zenith Technology Corporation, Limited | Synthetic skin substitutes |
US5206020A (en) * | 1991-01-15 | 1993-04-27 | Elizabeth Arden Company, Division Of Conopco, Inc. | Synthetic pseudoceramide and cosmetic compositions thereof |
US5468475A (en) * | 1992-11-17 | 1995-11-21 | Pola Chemical Industries Inc. | Cosmetic composition with choline derivative |
US5534499A (en) * | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
US5631012A (en) * | 1994-09-02 | 1997-05-20 | Shanni; David | Cosmetic preparations for moisturizing human skin containing specific lipids |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5776480A (en) * | 1994-12-14 | 1998-07-07 | L'oreal | Cosmetic or dermatological composition containing a mixture of ceramides for moisturizing the skin |
US5817856A (en) * | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
US5993830A (en) * | 1997-01-17 | 1999-11-30 | Ponsus Ab | Cosmetic skin preparation |
US6730288B1 (en) * | 1998-09-11 | 2004-05-04 | Connetics Australia Pty Ltd | Mousse composition |
US6153209A (en) * | 1999-09-28 | 2000-11-28 | The Procter & Gamble Company | Article having a transferable breathable skin care composition thereon |
US6497888B1 (en) * | 1999-10-14 | 2002-12-24 | L'ORéAL S.A. | Process for limiting the penetration into the skin and/or the keratinous fibres of an active cosmetic and/or pharmaceutical agent |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6824785B1 (en) * | 2000-02-09 | 2004-11-30 | C. Neil Kitson | Skin treatment composition and methods of use |
US6932963B2 (en) * | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090226491A1 (en) * | 2002-03-13 | 2009-09-10 | Thomas Skold | Water-based delivery systems |
US8029810B2 (en) | 2002-03-13 | 2011-10-04 | Thomas Skold | Water-based delivery systems |
US10406088B2 (en) | 2015-01-20 | 2019-09-10 | TetraDerm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
Also Published As
Publication number | Publication date |
---|---|
JP2005522463A (en) | 2005-07-28 |
EP1534213B1 (en) | 2013-04-24 |
KR101076335B1 (en) | 2011-10-26 |
KR20040091116A (en) | 2004-10-27 |
WO2003077861A3 (en) | 2005-03-24 |
EP1534213A2 (en) | 2005-06-01 |
JP4806519B2 (en) | 2011-11-02 |
US8029810B2 (en) | 2011-10-04 |
AU2003233396A1 (en) | 2003-09-29 |
CA2476859A1 (en) | 2003-09-25 |
CA2476859C (en) | 2011-09-20 |
US20090226491A1 (en) | 2009-09-10 |
AU2003233396B2 (en) | 2007-05-24 |
US20040009213A1 (en) | 2004-01-15 |
EP1534213A4 (en) | 2005-10-26 |
ES2411656T3 (en) | 2013-07-08 |
WO2003077861A2 (en) | 2003-09-25 |
NZ534377A (en) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2476859C (en) | Water-based delivery systems | |
JP3238264B2 (en) | Cosmetic composition for salicylic acid dosing and its preparation | |
US6316428B1 (en) | Topical moisturizing composition and method | |
CA1336762C (en) | Method and composition for treating and preventing dry skin disorders | |
Cevc | Drug delivery across the skin | |
ES2334207T3 (en) | COMPOSITIONS THAT INCLUDE TOCOFEROL PHOSPHATE DERIVATIVES COMPLEXES. | |
KR100921959B1 (en) | Multi-Emulsified Vesicles Comprising a Multi Lamellar Liposome and Phospholipid Monolayer Nanoliposomes | |
US11547665B2 (en) | Multiphasic compositions | |
CA3147460C (en) | Insoluble active substance carrier comprising transfersome | |
PT93935B (en) | METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TOPAL TREATMENT OF ACNE VULGAR CONTAINING CETOCONAZOLE | |
WO2006039667A2 (en) | Water-based delivery systems | |
KR20180131876A (en) | Stabilized ceramide complex using liposome technology and manufacturing process thereof and cosmetic composition containing the same | |
EP2769709B1 (en) | Pseudolipid complex mixture and a skin external application composition containing same | |
US20150283080A1 (en) | Stabilized dermatological delivery system for active ingredient compositions for topical administration to the skin | |
Patel et al. | Liposomes and the skin permeability barrier | |
AU2007211879A1 (en) | Water-based delivery systems | |
EP4180418A1 (en) | Novel sphingolipid containing branched-chain fatty acid and use thereof | |
Li et al. | Bioadhesive Liposomal Gel of Tetracaine with Enhanced Anaesthetic Activity Using Modern Permeation Enhancers: Optimization by Box-Behnken Statistical Design | |
KR20190085297A (en) | Polysaccharide liquid crystal composition and manufacturing method thereof and cosmetic composition comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GALDERMA LABORATORIES, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COLLAGENEX PHARMACEUTICALS, INC.;REEL/FRAME:022731/0739 Effective date: 20090427 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |